

---

*Research Articles: Neurobiology of Disease*

## **Maternal and Early Postnatal Immune Activation Produce Dissociable Effects on Neurotransmission in mPFC-Amygdala Circuits**

Yan Li<sup>1</sup>, Galen Missig<sup>1</sup>, Beate C. Finger<sup>1</sup>, Samantha M. Landino<sup>1</sup>, Abigail J. Alexander<sup>1</sup>, Emery Mokler<sup>1</sup>, James Robbins<sup>1</sup>, Yunona Manasian<sup>1</sup>, Woori Kim<sup>1</sup>, Kwang-Soo Kim<sup>1</sup>, Christopher J. McDougle<sup>2</sup>, William A. Carlezon<sup>1</sup> and Vadim Y. Bolshakov<sup>1</sup>

<sup>1</sup>Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA

<sup>2</sup>Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Lexington, MA 02421, USA

DOI: 10.1523/JNEUROSCI.3642-17.2018

Received: 27 December 2017

Revised: 13 February 2018

Accepted: 21 February 2018

Published: 28 February 2018

---

**Author contributions:** K.-S.K., C.J.M., W.A.C.J., and V.B. designed research; Y.L., G.M., B.C.F., S.M.L., A.J.A., E.M., J.R., Y.M., and W.K. performed research; Y.L., G.M., B.C.F., S.M.L., A.J.A., E.M., J.R., Y.M., and W.K. analyzed data; K.-S.K., C.J.M., W.A.C.J., and V.B. wrote the paper.

**Conflict of Interest:** The authors declare no competing financial interests.

We thank the Robert and Donna Landreth Family Foundation and the Nancy Lurie Marks Family Foundation for their generous support of this project.

**Correspondence should be addressed to:** Vadim Y. Bolshakov, , McLean Hospital, Harvard Medical School, Belmont, MA 02478, Tel: 617-855-3171, Email: [vadimb@mclean.harvard.edu](mailto:vadimb@mclean.harvard.edu), or to: William A. Carlezon, Jr., McLean Hospital, Harvard Medical School, Belmont, MA 02478, Tel: 617-855-2021, Email: [bcarlezon@mclean.harvard.edu](mailto:bcarlezon@mclean.harvard.edu)

**Cite as:** J. Neurosci ; 10.1523/JNEUROSCI.3642-17.2018

**Alerts:** Sign up at [www.jneurosci.org/cgi/alerts](http://www.jneurosci.org/cgi/alerts) to receive customized email alerts when the fully formatted version of this article is published.

Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process.

Copyright © 2018 the authors

1

2 **Maternal and Early Postnatal Immune Activation Produce Dissociable**  
3 **Effects on Neurotransmission in mPFC-Amygdala Circuits**

4

5 Yan Li<sup>1</sup>, Galen Missig<sup>1</sup>, Beate C. Finger<sup>1</sup>, Samantha M. Landino<sup>1</sup>, Abigail J. Alexander<sup>1</sup>,  
6 Emery Mokler<sup>1</sup>, James Robbins<sup>1</sup>, Yunona Manasian<sup>1</sup>, Woori Kim<sup>1</sup>, Kwang-Soo Kim<sup>1</sup>,  
7 Christopher J. McDougle<sup>2</sup>, William A. Carlezon, Jr<sup>1\*</sup>, and Vadim Y. Bolshakov<sup>1\*</sup>

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

<sup>1</sup>Department of Psychiatry, McLean Hospital  
Harvard Medical School  
Belmont, MA 02478, USA

<sup>2</sup>Lurie Center for Autism, Massachusetts General Hospital  
Harvard Medical School  
Lexington, MA 02421, USA

Correspondence should be addressed to:

Vadim Y. Bolshakov

McLean Hospital

Harvard Medical School

Belmont, MA 02478

Tel: 617-855-3171

Email: [vadimb@mclean.harvard.edu](mailto:vadimb@mclean.harvard.edu)

Text pages – 42 pages

Figures – 8 figures

Abstract – 250 words

Introduction – 649 words

Discussion – 964 words

or to:

William A. Carlezon, Jr.

McLean Hospital

Harvard Medical School

Belmont, MA 02478

Tel: 617-855-2021

Email: [bcarlezon@mclean.harvard.edu](mailto:bcarlezon@mclean.harvard.edu)

\*Equivalent senior authorship roles

Abbreviated Title: Role of Immune Activation in Autism

Acknowledgements: We thank the Robert and Donna Landreth Family Foundation and the Nancy Lurie Marks Family Foundation for their generous support of this project.

The authors declare no competing financial interests.

41 **Abstract**

42 Inflammatory processes may be involved in the pathophysiology of neuropsychiatric  
43 illnesses including Autism Spectrum Disorder (ASD). Evidence from studies in rodents  
44 indicates that immune activation during early development can produce core features of  
45 ASD (social interaction deficits, dysregulation of communication, increases in  
46 stereotyped behaviors and anxiety), although the neural mechanisms of these effects  
47 are not thoroughly understood. We treated timed-pregnant mice with  
48 polyinosinic:polycytidylic acid (Poly I:C), which simulates a viral infection, or vehicle on  
49 gestational day 12.5 to produce maternal immune activation (MIA). Male offspring  
50 received either vehicle or lipopolysaccharide (LPS), which simulates a bacterial infection,  
51 on postnatal day 9 to produce postnatal immune activation (PIA). We then used  
52 optogenetics to address the possibility that early developmental immune activation  
53 causes persistent alterations in the flow of signals within the medial prefrontal cortex  
54 (mPFC) to basolateral amygdala (BLA) pathway, a circuit implicated in ASD. We found  
55 that our MIA regimen produced increases in synaptic strength in glutamatergic  
56 projections from the mPFC to the BLA. In contrast, our PIA regimen produced  
57 decreases in feed-forward GABAergic inhibitory postsynaptic responses resulting from  
58 activation of local circuit interneurons in the BLA by mPFC-originating fibers. Both  
59 effects were seen together when the regimens were combined. Changes in the balance  
60 between excitation and inhibition were differentially translated into the modified spike  
61 output of BLA neurons. Our findings raise the possibility that prenatal and postnatal  
62 immune activation may affect different cellular targets within brain circuits that regulate  
63 some of the core behavioral signs of conditions such as ASD.

64 **Significance Statement**

65 Immune system activation during prenatal and early postnatal development may  
66 contribute to the development of Autism Spectrum Disorder (ASD). Combining  
67 optogenetic approaches and behavioral assays that reflect core features of ASD  
68 (anxiety, decreased social interactions), we uncovered mechanisms by which the ASD-  
69 associated behavioral impairments induced by immune activation could be mediated at  
70 the level of interactions within brain circuits implicated in control of emotion and  
71 motivation (mPFC and BLA, specifically). In this article, we present evidence that  
72 prenatal and postnatal immune activation can have different cellular targets in the brain,  
73 providing support to the notion that the etiology of ASD may be linked to the  
74 excitation/inhibition imbalance in the brain affecting the signal flow within relevant  
75 behavior-driving neural microcircuits.

76

77

78

79

80

81

82

83

84

85

86

87 Accumulating evidence suggests that the immune system is involved in  
88 neuropsychiatric conditions including autism spectrum disorder (ASD) (Miller et al.,  
89 2017). ASD comprises a group of neurodevelopmental disorders with distinctive  
90 behavioral manifestations and complex underlying mechanisms (Markram and Markram,  
91 2010). The contribution of genetic factors to some forms of ASD is well established  
92 (Abrahams and Geschwind, 2008; Betancur, 2011; O'Roak et al., 2012; Talkowski et al.,  
93 2014). However, environmental factors, including those that trigger immune responses,  
94 may also play a role in the etiology of ASD (Onore et al., 2012; McDougle et al., 2015;  
95 Lombardo et al., 2017; Meltzer and Van de Water, 2017). Several studies have shown  
96 that viral infection during the second-trimester of pregnancy is associated with an  
97 increased risk of ASD (Patterson, 2009; Atladóttir et al., 2010; Zerbo et al., 2011;  
98 Knuesel et al., 2014; Patel et al., 2017). Consistent with the results of studies in  
99 humans, immune system activation in laboratory animals can recapitulate key aspects  
100 of ASD, supporting the notion that immunoactivation in the brain could lead to the  
101 development of functional abnormalities characteristic of ASD (Smith et al., 2007;  
102 Sangha et al., 2014; Canetta et al., 2016; Choi et al., 2016).

103

104 It is becoming increasingly clear that ASD is a neural network phenomenon that may  
105 reflect dysregulation of functional interactions between brain regions, controlling specific  
106 behavioral domains. Typically, aberrant social interactions, communication deficits, and  
107 increases in stereotyped behaviors are considered to be the primary diagnostic features  
108 of ASD, but these signs are frequently co-morbid with other features including enhanced  
109 anxiety. The neurocircuits underlying social interaction and anxiety-related behaviors

110 are well defined and include the medial prefrontal cortex (mPFC) and the amygdala  
111 (AMG) (Baron-Cohen et al., 1999; Markram and Markram, 2010). Accordingly, there is  
112 increasing interest in the possibility that ASD-associated behavioral impairments may  
113 be linked to dysfunction within these neural circuits. It has been demonstrated in  
114 genetic and valproic acid exposure models that the development of ASD-like behavioral  
115 signs is associated with hyperconnectivity within the mPFC (Rinaldi et al., 2008; Sui and  
116 Chen, 2012; Testa-Silva et al., 2012). This could increase activation of target areas  
117 receiving projections from the mPFC, including the AMG. Because the AMG is a key  
118 component of the brain circuits underlying anxiety-related behaviors (LeDoux, 2000),  
119 increased mPFC-AMG functional connectivity might contribute to features of anxiety  
120 and social avoidance seen in ASD.

121

122 Previous studies have implicated the activity of projections from the mPFC to the AMG  
123 in control of anxiety and fear (Maren and Quirk, 2004; Pape and Pare, 2010). It remains  
124 unknown, however, whether the development of ASD features is associated with altered  
125 neurotransmission in the mPFC-BLA pathway. Using optogenetic techniques (Boyden  
126 et al., 2005), we addressed this question in a “two hit” mouse model (Harvey and Boksa,  
127 2012; Giovanoli et al., 2013), exploring the possibility that early developmental immune  
128 activation can increase the prevalence of ASD-associated dysfunctions (Mrozek-Budzyn  
129 et al., 2013; Hadjkacem et al., 2016). In this model, mice received a maternal immune  
130 activation (MIA) challenge on embryonic day 12.5 (E12.5) with polyinosinic:polycytidylic  
131 acid (Poly I:C)—a toll-like receptor 3 [TLR3] agonist simulating an innate immune  
132 response to a virus—with or without a subsequent postnatal immune activation (PIA)

133 challenge with lipopolysaccharide (LPS)—a TLR4 agonist simulating an innate immune  
134 response to bacteria—on postnatal day 9 (PND9) (Smith et al., 2007; Kawai and Akira,  
135 2008; Reisinger et al., 2015; Canetta et al., 2016; Choi et al., 2016; Custódio et al.,  
136 2017; Patel et al., 2017). This approach aligns with TLR expression patterns (Barak et  
137 al., 2014) and infection risk factors seen in humans (Bilbo et al., 2009). We then  
138 examined neurotransmission in mPFC-BLA projections in the treatment groups. We  
139 found that our MIA regimen significantly enhanced glutamatergic synaptic transmission  
140 in mPFC-BLA projections, whereas our PIA regimen significantly diminished feed-  
141 forward inhibition in the same pathway, suggesting that these immune challenges act  
142 upon different cellular targets in the brain.

143

#### 144 **Materials and Methods**

145 *Animal model of maternal and postnatal immunoactivation.* The McLean Hospital  
146 Institutional Animal Care and Use Committee approved all animal procedures in this  
147 study. Timed pregnant Jackson Laboratory mice (C57BL6J) were obtained by housing  
148 a female and male pair overnight. The following morning pairs were separated and mid-  
149 day was considered embryonic day 0.5 (E0.5). Pregnancy was identified by body  
150 weight gain and physical appearance. At E12.5 pregnant dams received an  
151 intraperitoneal (IP) injection of either 20 mg/kg Poly I:C (catalog #P9852, Sigma-Aldrich,  
152 St. Louis, MO, USA) or vehicle (sterile phosphate buffered saline, PBS). The dosing of  
153 poly I:C and its route of administration were as in previously published studies (Smith et  
154 al., 2006; Choi et al., 2016). Dams were monitored for parturition. Male offspring of  
155 these mice (1 – 5 mice per litter) were used in our experiments. On postnatal day 9

156 (PND9), pups received a subcutaneous (SC) injection of 10 mg/kg LPS from  
157 *Escherichia coli* 0111:B4 (catalog #L3024, Sigma-Aldrich, St. Louis, MO, USA) or  
158 vehicle (endotoxin-free saline). The optimal dose of LPS and an efficient route of its  
159 administration were determined empirically in control studies. P9 in rodents  
160 approximately corresponds to 39-40-week human gestation (term infant; Semple et al.,  
161 2013; Custodio et al., 2017). Thus, we used the regimen providing bacterial challenge  
162 at P9 to mimic the environmental challenges which human newborns could meet very  
163 early postnatally.

164

165 *Microglia immunohistochemistry and quantitative analysis.* To confirm the presence of  
166 treatment-induced inflammatory responses in the brain, we examined brain microglia.  
167 Mice were deeply anesthetized with pentobarbital and transcardially perfused with  
168 phosphate buffered saline, followed by 4% paraformaldehyde. Brains were dissected,  
169 post-fixed in 4% paraformaldehyde overnight at 4°C, equilibrated to 30% sucrose, and  
170 then cryosectioned. Sections (30 µm) containing the BLA were permeabilized with  
171 0.3% Triton X-100, blocked with 1% bovine serum albumin and 2% normal donkey  
172 serum, and then incubated with 1:400 rabbit anti-IBA-1 antibody (019-19471, Wako  
173 Chemicals, Osaka, Japan) overnight at 4°C. After rinses, sections were incubated in  
174 1:200 anti-rabbit AlexaFluor 488 antibody for 2 hours, stained with DAPI (0.5µg/ml),  
175 rinsed, and then mounted on slides. Images were obtained with a 40x objective using a  
176 confocal laser-scanning microscope (TCS SP8, Leica, Wetzlar, Germany) of the  
177 identical portion of the BLA. 5 µm z-stacks were obtained at Nyquist-derived optimal  
178 section thickness. All images were acquired under identical settings and parameters,

179 and then exported to ImageJ software (NIH) for analysis. Maximum projections were  
180 made and the total threshold signal per unit area, cell count, soma size, or ramifications  
181 of each image were quantified by semi-autonomous methods or by using a blinded  
182 scorer in ImageJ. The co-localization of DAPI and IBA-1 immunoreactivity was used to  
183 identify individual cells.

184

185 *Behavioral tests.* Effects of MIA or PIA alone on ASD-like behaviors have been  
186 reported (Smith et al., 2007; Custódio et al., 2017). To confirm treatment-induced  
187 changes in behavior, we used the open field to quantify anxiety-like responses,  
188 considering that anxiety is frequently co-morbid with ASD. Mice were placed in the  
189 corner of a brightly lit open field (44 cm x 44 cm x 30 cm) and allowed to freely explore  
190 for 10 minutes while being video recorded. The percentage of time the mouse spent in  
191 the center of the open field and total distance travel was analyzed using Ethovision-XT  
192 (Noldus Information Technology, Wageningen, the Netherlands). The social interaction  
193 test (Golden et al., 2011; Bagot et al., 2015) consisted of two separate 3-minute  
194 sessions. The first session consisted a mouse being placed in a chamber (44 cm x 44  
195 cm x 30 cm) that contained an empty metal wire cage (10 cm x 8 cm x 6 cm) at the  
196 other end of the arena. In the second session an age-matched and sex-matched novel  
197 conspecific was placed in the metal cage, preventing direct physical contact. The  
198 duration of time in the interaction zone was calculated for both the empty cage and  
199 conspecific sessions using automated tracking software (Noldus Ethovision-XT 7.0).  
200 Data is presented as the social interaction ratio (mouse/empty interaction zone time)  
201 normalized to the Veh\_Veh group.

202

203 *Viral constructs.* We used adeno-associated virus (AAV) carrying channelrhodopsin-  
204 2(H143R)-eYFP under control of CaMKII $\alpha$  promoter to investigate functional  
205 connectivity in the mPFC-AMG circuits. Vectors were purchased from the viral vector  
206 core facility at the University of North Carolina, and the titers were  $\sim 10.0 \times 10^{12}$   
207 particles/ml.

208

209 *Stereotaxic surgery and viral injections.* Surgeries were performed by using medical  
210 and laboratory aseptic techniques. Male offspring of immunoactivated mice (8-10  
211 weeks old) were anesthetized with a mixture of ketamine and xylazine (160 mg/kg and  
212 12 mg/kg body weight, respectively). The surgical procedures and viral injections were  
213 performed as previously described (Cho et al., 2013). Briefly, bilateral craniotomy was  
214 made to target the prelimbic cortex (PL) of the medial prefrontal cortex (mPFC) using  
215 the stereotaxic coordinates: 1.8 mm rostral to Bregma,  $\pm 0.4$  mm lateral to midline, and  
216 1.8 mm ventral to the skull surface (Franklin and Paxinos, 2007). The AAV vector  
217 carrying channelrhodopsin-2(H143R)-eYFP was injected bilaterally into PL at a rate of  
218 0.1  $\mu$ l/minute under control of the syringe pump (Stoelting Co.). Mice were given 0.1 ml  
219 ketoprofen (SC) (Boehringer Ingelheim) to reduce pain. After surgery, mice were single  
220 housed for 8 weeks before behavioral or *ex vivo* electrophysiological experiments.

221

222 *Ex vivo electrophysiology and photostimulation.* After cervical dislocation and  
223 decapitation, brains were removed and coronal slices (300  $\mu$ m) containing the mPFC or  
224 the AMG were obtained using a vibratome in cold cutting solution containing: 252 mM

225 sucrose, 1.0 mM CaCl<sub>2</sub>, 5.0 mM MgCl<sub>2</sub>, 2.5 KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>,  
226 10 mM glucose and equilibrated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. Slices were then incubated  
227 in oxygenated artificial cerebrospinal fluid (ACSF) containing: 125 mM NaCl, 2.5 mM  
228 KCl, 2.5 mM CaCl<sub>2</sub>, 1.0 mM MgSO<sub>4</sub>, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 26 mM NaHCO<sub>3</sub> and 10 mM  
229 glucose at room temperature for at least one hour before electrophysiological  
230 recordings. The subnuclei of the AMG were visualized under a Zeiss microscope  
231 coupled with an IR-camera (Hamamatsu, Japan) and defined based on the structural  
232 landmarks of the internal capsule (ic) and the external capsule (ec). Whole-cell  
233 recording were obtained from neurons in the BLA with patch electrodes (3-5 MΩ  
234 resistance) containing: 130 mM Cs-methane-sulfonate, 5.0 mM KCl, 2.5 mM NaCl, 1.0  
235 mM MgCl<sub>2</sub>, 10 mM BAPTA, 10 mM HEPES, 2 mM MgATP, and 0.1 mM NaGTP  
236 (adjusted to pH 7.2 with KOH). Qx-314 (5 mM) and spermine (0.5 mM) were added in  
237 the internal solution before the recordings. To assay membrane properties and record  
238 photostimulation-induced action potentials in the mPFC (Fig. 2D), 130 mM K-gluconate  
239 was used instead of Cs-methane-sulfonate in the pipette solution. Neurobiotin (0.2%,  
240 Vector Labs) was added into the internal pipette solution to locate the recorded neurons  
241 in the the amygdala. Synaptic responses were induced by photostimulation of ChR2-  
242 expressing mPFC projecting fibers in the BLA through a 40x water-immersion objective  
243 lens (Carl Zeiss microscope) with a LED light source (excitation wavelength: 470 nm, 1  
244 ms in duration, Thorlabs). All whole-cell recordings were performed at 30-32°C in the  
245 external medium. Current were filtered at 1 kHz and digitized at 5 kHz. After  
246 recordings, slices were placed in PBS containing 4% paraformaldehyde and kept in a  
247 refrigerator until histological processing.

248

249 To minimize the variability in photostimulation-induced synaptic responses between  
250 experimental groups, the volume of ChR2-encoding virus infused in the mPFC,  
251 coordinates of the PL and the expression time of ChR2 in the brain were kept constant  
252 throughout the study. Before the recordings, the extent and intensity of ChR2-eYFP  
253 expression at the injection site in acute slices containing the mPFC and ChR2-  
254 expressing fibers in the AMG (projection site) were evaluated under low (10x)  
255 magnification. To assay the effects of immunoactivation on functional expression of  
256 ChR2 in the brain, the amplitude of photostimulation-induced currents and the reliability  
257 of photostimulation-induced action potentials were examined in pyramidal neurons  
258 in layer V at the ChR2 injection site in the PL (Fig. 2C,D).

259

260 Pharmacological reagents used in the electrophysiological experiments, which included  
261 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[*f*]quinoxaline-7-sulfonamide (NBQX) disodium  
262 salt, D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), *N*-(2,6  
263 dimethylphenylcarbamoylmethyl)triethylammonium (QX 314) chloride, (-)-bicuculline  
264 methobromide (from R&D Systems), and spermine tetrahydrochloride (from Sigma-  
265 Aldrich), were prepared as stock solutions in water at 1000- to 5000-fold concentrations  
266 and stored at -20°C.

267

268 *Histology.* Brain slices were washed in PBS (3 X 15 min) and incubated in 0.1% Triton  
269 PBS containing neurotracer fluorescent Nissl stain (diluted 40X, Molecular Probes) for 1  
270 hr at room temperature, and then re-washed in PBS (3 X 20 min). Sections containing

271 neurobiotin loaded cells were incubated in 0.1% Triton PBS containing Streptavidin Alexa  
272 568 conjugate (20 µg/ml, Molecular Probes) for 2 hr at room temperature, and then  
273 washed in PBS (3 X 20 min). Finally, sections were mounted on the gelatinized slides,  
274 dehydrated and coverslipped. Vectashield mounting medium (Vector Laboratory) was  
275 applied to slices to prevent fluorescence fading. Viral vector infusion sites were examined  
276 under Leica TCS SP8 confocal microscope (Leica) or Zeiss Axioskop 2 fluorescent  
277 microscope (Carl Zeiss). Mice in which the injection missed the target (PL mPFC) were  
278 excluded from the analysis.

279

280 *Analysis of mPFC projection patterns in the amygdala.* To detect the effect of  
281 immunoactivation on mPFC projection patterns in different subnuclei of the AMG, the  
282 fluorescence intensity of ChR2-eYFP-expressing fibers within the subregion were  
283 quantitatively analyzed. Confocal fluorescent images were acquired using a Leica TCS  
284 SP8 confocal microscope (Leica) using a 10/0.40 NA objective lens. The settings for  
285 aperture gain, laser intensity and offset were optimized initially and then kept constant  
286 throughout the acquisition of images from all mice used for the analysis. Confocal z-  
287 stack images of ChR2-eYFP-expressing fibers in the amygdala contained 6-12 images  
288 which were captured 5 µm apart. The boundary of the subnuclei of the amygdala was  
289 defined based on landmark structures (internal and external capsules) and cellular  
290 morphology (Sah et al., 2003) revealed by fluorescent Nissl (and DAPI) counterstain.  
291 The fluorescence intensity on a single focal plane in the channel for ChR2-eYFP was  
292 measured using ImageJ (1.51f, National Institutes of Health, USA).

293

294 *Sholl analysis.* To detect the effect of immune activation on neuronal structure, we  
295 reconstructed 32 neurobiotin-filled BLA neurons from all four experimental groups (8  
296 neurons per group). The recorded and subsequently reconstructed cells were identified  
297 as neurons based on their accommodating firing patterns (Tsvetkov et al., 2002).  
298 Neurobiotin (6.0 mM) was added to the intrapipette solution. Stained neurons were  
299 scanned with a Leica confocal microscope under 40x/1.30 NA objective lens. Confocal  
300 z-stack images were processed using ImageJ and then reconstructed in the  
301 NeuronStudio program (Version 0.9.92). As the program automatically determines the  
302 3D position and branch diameter based on the imaging data, we used the manual  
303 tracing tool to trace each branch analyzed. Specifically, we were starting the manual  
304 tracing from the beginning of each primary dendrite, and were moving one node at a  
305 time to form an entire path along a branch in the 2D or 3D window. The image of a  
306 reconstructed neuron in Fig. 5A was generated with NeuroLucida 360 (MBF Bioscience).  
307 The dendritic length, dendritic surface area and the number of branch points were  
308 measured using Sholl analysis (Sholl, 1953). Soma size was estimated by its largest  
309 projection area of stack images, measured in ImageJ.

310

311 *Experimental design and statistical analysis.* Mice were randomly assigned to  
312 experimental groups. In electrophysiological experiments, one neuron was recorded  
313 per a slice. The numbers of mice and recorded neurons used for the analysis in  
314 different experiments are indicated in the figure legends. Data are reported as means  $\pm$   
315 the standard error of the mean (SEM). The experiments were conducted using a 2x2  
316 factorial design (Fig. 1A), and results were analyzed with two-way or three-way ANOVA

317 when appropriate to assess main effects of either Poly I:C or LPS as well as of a third  
318 factor when it was present (such as light power density, stimulation frequency, Bregma  
319 plane, or distance from soma), and interaction effects, followed by post-hoc *Bonferroni's*  
320 simultaneous multiple comparisons of each treatment group to Veh\_Veh. When  
321 appropriate, *Student's* two-tailed paired *t*-test was used. Statistical analysis was  
322 performed with SigmaPlot 13.0 or Minitab 16. The results of the statistical analysis are  
323 presented in the text or in the figure legends.

324

## 325 **RESULTS**

### 326 **Immune activation results in alterations of microglia in the BLA and leads to ASD-** 327 **linked behavioral impairments**

328 To investigate whether *in utero* and/or early life neuroinflammation could alter the signal  
329 flow in the mPFC-AMG circuits and produce ASD-relevant behavioral dysfunction, we  
330 administered either Poly I:C (20 mg/kg, IP) or vehicle (PBS) to pregnant female  
331 C57BL/6J mice on day 12.5 of pregnancy (as in Smith et al., 2007). Subsequently,  
332 male offspring from both groups (Poly I:C or vehicle-injected mothers) were injected  
333 either with LPS (10 mg/kg; Poly I:C\_LPS and Veh\_LPS groups) or vehicle on postnatal  
334 day 9.5 (PND9; Poly I:C\_Veh and Veh\_Veh groups) (Fig. 1A). Poly I:C binds to TLR3,  
335 triggering production of type I interferons, whereas LPS activates TLR4 resulting in  
336 release of TNF- $\alpha$  from macrophages (reviewed in Lombardo et al., 2017). Notably, Poly  
337 I:C-induced neuroinflammation in pregnant mice is associated with activation of cytokine  
338 signaling mediated by interleukin-6, capable of passing from a pregnant female through  
339 the placenta to the fetal brain (Lombardo et al., 2017). Since it has been shown

340 previously that Poly I:C-induced MIA leads to lasting alterations of microglia in the  
341 offspring mice exhibiting characteristics of the microglial hyperactive state (Krstic et al.,  
342 2012; Knuesel et al., 2014), we performed immunostaining for a microglial marker,  
343 Ionized calcium binding adaptor molecule 1 (IBA-1), in 13-week-old offspring mice. In  
344 our analysis, we focused on the BLA, where prefrontal projection fibers were  
345 predominantly found (see below). We found that both the number of IBA-1 positive cells  
346 and the intensity of IBA-1 (Fig. 1B,C) staining (immunoreactivity, IR) were increased in  
347 the offspring groups receiving the postnatal LPS injections, indicating an activation of  
348 microglia approximately 12 weeks after the LPS injection at PND9 (Fig. 1C, left: two-  
349 way ANOVA, Poly I:C,  $F_{(1,18)} = 0.356$ ,  $p = 0.558$ ; LPS,  $F_{(1,18)} = 25.821$ ,  $p < 0.001$ ;  
350 interaction,  $F_{(1,18)} = 0.241$ ,  $p = 0.629$ ; post-hoc *Bonferroni's* test:  $P < 0.009$  for Veh\_Veh  
351 versus Veh\_LPS and  $P = 0.003$  for Veh\_Veh versus Poly I:C\_LPS; Fig. 1C, right: two-way  
352 ANOVA, Poly I:C,  $F_{(1,18)} = 0.538$ ,  $p = 0.473$ ; LPS,  $F_{(1,18)} = 17.538$ ,  $p < 0.001$ ; interaction,  
353  $F_{(1,18)} = 0.108$ ,  $p = 0.747$ ; post-hoc *Bonferroni's* test:  $p < 0.05$  for Veh\_Veh versus  
354 Veh\_LPS or for Veh\_Veh versus Poly I:C\_LPS). There were no significant differences  
355 in microglial soma size or the number of microglial ramifications between experimental  
356 groups (Fig. 1D; soma size: two-way ANOVA, Poly I:C,  $F_{(1,234)} = 3.334$ ,  $p = 0.069$ ; LPS,  
357  $F_{(1,234)} = 0.462$ ,  $p = 0.497$ ; interaction,  $F_{(1,234)} = 2.339$ ,  $p = 0.128$ ; number of ramifications:  
358 two-way ANOVA, Poly I:C,  $F_{(1,234)} = 3.238$ ,  $p = 0.073$ ; LPS,  $F_{(1,234)} = 1.268$ ,  $p = 0.261$ ;  
359 interaction,  $F_{(1,234)} = 0.019$ ,  $p = 0.892$ ).

360

361 Accompanying these inflammatory markers, there were group differences in anxiety and  
362 social behavior. Thus, mice in the Veh\_LPS group exhibited increased anxiety-like

363 behavior in the open field test (Briton et al., 1981; File et al., 1985; Riccio et al., 2009;  
364 Riccio et al., 2014). Specifically, these mice spent less time in the center of the open  
365 field compared to the Veh\_Veh group (Fig. 1E), which is commonly interpreted as an  
366 increased anxiety-like behavioral response (Lezak et al. 2017). This effect was not due  
367 to decreased locomotor activity because animals in the Veh\_LPS group did not differ  
368 from mice in the control Veh\_Veh group in the total distance traveled (Fig. 1E). Notably,  
369 mice in the Poly I:C\_LPS group also showed increased anxiety-like responses (Fig. 1E;  
370 time in center (%): two-way ANOVA, Poly I:C,  $F_{(1,78)} = 2.291$ ,  $p = 0.134$ ; LPS,  $F_{(1,78)} =$   
371  $17.052$ ,  $p < 0.001$ ; interaction,  $F_{(1,78)} = 0.008$ ,  $p = 0.928$ ; post-hoc *Bonferroni's* test:  $p <$   
372  $0.05$  for Veh\_Veh versus Veh\_LPS and  $p < 0.001$  for Veh\_Veh versus Poly I:C\_LPS).  
373 In this experimental group, the total distance traveled was increased compared to  
374 Veh\_Veh control mice (Fig. 1E, distance traveled: two-way ANOVA, Poly I:C,  $F_{(1,78)} =$   
375  $4.293$ ,  $p = 0.042$ ; LPS,  $F_{(1,78)} = 3.275$ ,  $p = 0.074$ ; interaction,  $F_{(1,78)} = 0.014$ ,  $p = 0.906$ ;  
376 post-hoc *Bonferroni's* test:  $p < 0.05$  for Veh\_Veh versus Poly I:C\_LPS). However, it is  
377 unlikely that slight increases in locomotor activity can explain the enhanced  
378 anxiogenesis in Poly I:C\_LPS mice, as enhanced locomotion may slightly blunt anxiety-  
379 like responses rather than promote them due to the fact that more actively moving mice  
380 could randomly cross into the anxiogenic center more often. In agreement with the role  
381 of immune activation in the development of ASD-linked behavioral dysfunctions, we also  
382 found that social interactions were diminished in our experimental groups. Thus, mice  
383 in both Veh\_LPS and Poly I:C\_LPS groups spent less time in the interaction zone with  
384 the novel conspecific mouse (Fig. 1F, left, two-way ANOVA, Poly I:C,  $F_{(1,54)} = 2.397$ ,  $p =$   
385  $0.127$ ; LPS,  $F_{(1,54)} = 10.157$ ,  $p = 0.002$ ; interaction,  $F_{(1,54)} = 1.923$ ,  $p = 0.171$ ; post-hoc

386 *Bonferroni's* test:  $p = 0.014$  for Veh\_Veh group versus Veh\_LPS group and  $p = 0.004$   
387 for Veh\_Veh versus Poly I:C\_LPS). However, there was no treatment effect on the  
388 distance traveled during the social interaction test (Fig. 1F, right, two-way ANOVA, Poly  
389 I:C,  $F_{(1,54)} = 0.161$ ,  $p = 0.69$ ; LPS,  $F_{(1,54)} = 0.313$ ,  $p = 0.578$ ; interaction,  $F_{(1,54)} = 0.109$ ,  $p$   
390  $= 0.743$ ).

391

392 Together, these findings indicate that perinatal immune activation can trigger long-  
393 lasting alterations in brain and behavior.

394

#### 395 **Projection-specific optogenetic targeting of mPFC-amygdala circuits**

396 To target neuronal projections from mPFC to AMG for the subsequent functional  
397 analysis, we expressed channelrhodopsin2 (ChR2) in the mPFC by stereotaxically  
398 injecting AAV5-CamKII $\alpha$ -ChR2-eYFP) in mice from all four experimental groups (Fig.  
399 2A). Eight weeks after gene transfer, eYFP-tagged ChR2 was densely expressed at the  
400 injection site (Fig. 2B). Although the tip of an injection pipette was placed within the  
401 prelimbic mPFC (PL), the ChR2-eYFP-mediated green fluorescent signal was also  
402 observed in the infralimbic mPFC (IL), suggesting that both IL- and PL-originating  
403 projections were activated in these experiments. Notably, we found previously that the  
404 IL and PL projection patterns to the AMG are virtually identical (Cho et al., 2013). By  
405 performing whole-cell recordings from virally transduced neurons, we confirmed the  
406 functionality of ChR2 expression at the mPFC injection site. Delivery of prolonged  
407 pulses of blue light (470 nm) of increasing intensity triggered inward currents with  
408 transient and sustained components in recorded neurons under voltage-clamp

409 recording conditions at a holding potential of -80 mV (Fig. 2C). We did not observe  
410 differences in the peak photocurrent amplitude between the groups, indicating that  
411 neither MIA nor PIA had effects on ChR2 expression in the mPFC (Fig. 2C; three-way  
412 ANOVA (Poly I:C x LPS x light power density); Poly I:C,  $F_{(1,474)} = 0.199$ ,  $p = 0.651$ ; LPS,  
413  $F_{(1,474)} = 0.003$ ,  $p = 0.986$ ; interaction,  $F_{(5,474)} = 0.227$ ,  $p = 0.951$ ). In current-clamp  
414 recordings, short (5-ms-long) pulses of blue light evoked action potential (AP) firing, with  
415 spikes reliably following higher frequencies of photostimulation (up to 40 Hz) (Fig. 2D).  
416 Consistent with the lack of the effect of neuroinflammation on the ability of ChR2 to  
417 drive neuronal spiking, the input-output curves for the probability of AP firing in  
418 response to trains of photostimuli of increasing frequency did not differ between the  
419 experimental groups (Fig. 2D; three way-way ANOVA (Poly I:C x LPS x stimulation  
420 frequency); Poly I:C,  $F_{(1,103)} = 0.0003$ ,  $p = 0.996$ ; LPS,  $F_{(1,103)} = 2.425$ ,  $p = 0.122$ ;  
421 interaction,  $F_{(3,103)} = 0.967$ ,  $p = 0.411$ ).

422

423 Consistent with previous reports (Cho et al., 2013), the ChR2-eYFP-expressing fibers  
424 arising from the virally-transduced neurons in the mPFC were found predominantly in  
425 the BLA (Fig. 3). We confirmed that mPFC projections form functional synapses on  
426 neurons in the BLA by performing whole-cell recordings from these cells and triggering  
427 the excitatory postsynaptic currents (EPSCs) in them in voltage-clamp mode at -80 mV  
428 by 5-ms pulses of blue light (Fig. 3A). The EPSCs at the mPFC-BLA synapses were  
429 glutamatergic, as indicated by their sensitivity to NBQX (10  $\mu$ M), an  $\alpha$ -amino-3-hydroxy-  
430 5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptor antagonist (Fig. 3A).  
431 Synaptic responses were suppressed by tetrodotoxin (TTX, 1  $\mu$ M), a sodium channel

432 blocker, providing evidence that they were mediated by presynaptic action potential  
433 firing (as in Cho et al., 2013). Under these recording conditions, the glutamatergic  
434 EPSCs in mPFC-AMG projections are monosynaptic, as they could be rescued by an  
435 exogenously-applied blocker of voltage-gated K<sup>+</sup> channels, 4-aminopyridine (4-AP)  
436 when the EPSCs were blocked by TTX (Petreanu et al., 2009; Cho et al., 2013; Fig.  
437 3C,D). In agreement with our previous report (Cho et al., 2013), photostimulation of  
438 mPFC fibers induced EPSCs in all recorded BLA neurons (140 neurons) and in most  
439 intercalated cells (ITCs; 81.8%, 27 out of 33 neurons (Fig. 3B) (but see Strobel et al.,  
440 2015, and Luchkina and Bolshakov, 2017 for discussion of possible reasons of why  
441 monosynaptic mPFC inputs to ITCs were not detected in Strobel et al., 2015). ITCs  
442 possess very high membrane resistance (>1.0 GOhm) and thus could be reliably  
443 identified in slice recordings (Cho et al., 2013). The synaptic connectivity between the  
444 mPFC and lateral nucleus of the amygdala (LA) or lateral subnucleus of the central  
445 amygdala (CeL) was very sparse (in LA, 25%, 7 out of 28 neurons exhibited synaptic  
446 responses; in CeL, 20%, 7 out of 35 neurons). Notably, we found that neither MIA, PIA  
447 nor MIA + PIA affected the fraction of BLA neurons or ITCs (relative to the total number  
448 of recorded cells) in which photostimulation-induced EPSCs could be observed at the  
449 maximum light intensity of 10.5 mW/mm<sup>2</sup> (Fig. 3B).

450

451 We also compared the fluorescence intensity of ChR2-eYFP-expressing mPFC  
452 projections in various parts of the AMG in brain slices between all experimental groups  
453 along the rostral-caudal axis at three different Bregma levels (Fig. 3E,F; see Materials  
454 and Methods for the quantification details). Consistent with the lack of a treatment

455 effect on the functional synaptic connectivity at mPFC projections to LA and CeL, the  
456 mean density of Chr2-eYFP fluorescence in these two AMG subnuclei remained  
457 unchanged (Fig. 3H,I; LA: three-way ANOVA (Poly I:C x LPS x Bregma plane); Poly I:C,  
458  $F_{(1,54)} = 0.037$ ,  $p = 0.849$ ; LPS,  $F_{(1,54)} = 0.012$ ,  $p = 0.914$ ; interaction,  $F_{(2,53)} = 0.128$ ,  $p =$   
459  $0.88$ ; CeL: three-way ANOVA (Poly I:C x LPS x Bregma plane), Poly I:C,  $F_{(1,53)} = 0.138$ ,  
460  $p = 0.712$ ; LPS,  $F_{(1,53)} = 1.321$ ,  $p = 0.256$ ; interaction,  $F_{(2,53)} = 0.137$ ,  $p = 0.872$ ).  
461 However, the fluorescence density was significantly enhanced in the BLA of mice from  
462 the Poly I:C\_LPS group (Fig. 3G; BLA: three-way ANOVA (Poly I:C x LPS x Bregma  
463 plane); Poly I:C,  $F_{(1,53)} = 3.57$ ,  $p = 0.064$ ; LPS,  $F_{(1,53)} = 9.178$ ,  $p = 0.004$ ; interaction,  
464  $F_{(2,53)} = 0.320$ ,  $p = 0.728$ ; post-hoc Bonferonni's simultaneous multiple comparisons:  $p =$   
465  $0.003$  for Veh\_Veh versus Poly I:C\_LPS), suggesting that the innervation of BLA by  
466 mPFC fibers might be increased in the MIA+PIA group.

467

468 **Prenatal MIA but not PIA is associated with synaptic strengthening at**  
469 **glutamatergic projections from mPFC to BLA**

470 We examined the effects of immunoactivation on synaptic transmission in the mPFC-  
471 BLA projections by performing whole-cell patch-clamp recordings of the light-induced  
472 EPSCs in BLA neurons in brain slices obtained from all experimental treatment groups  
473 (Veh-Veh, Poly I:C-Veh, Veh\_LPS or Poly I:C\_LPS; see above for details) (Fig. 4A-C).  
474 EPSCs were recorded in voltage-clamp mode at a holding potential of -80 mV. There  
475 were no treatment-induced alterations in the passive membrane properties of BLA  
476 neurons (Table 1). However, we found that synaptic strength, as quantified by input-  
477 output curves for EPSCs induced by the 1-ms pulses of blue light, was significantly

478 increased in both Poly I:C\_Veh and Poly I:C\_LPS groups compared to control Veh-Veh  
479 mice (Fig. 4C,D; three-way ANOVA (Poly I:C x LPS x light power density), Poly I:C,  
480  $F_{(1,798)} = 54.262$ ,  $p < 0.001$ ; LPS,  $F_{(1,798)} = 0.049$ ,  $p = 0.825$ ; interaction,  $F_{(5,798)} = 0.305$ ,  $p$   
481  $= 0.91$ ; post-hoc *Bonferroni's* simultaneous multiple comparisons:  $p = 0.003$  for  
482 Veh\_Veh versus Poly I:C\_Veh and  $p < 0.001$  for Veh\_Veh versus Poly I:C\_LPS). The  
483 lack of a detectable effect in these experiments on the magnitude of mPFC-BLA EPSCs  
484 in the Veh\_LPS group indicates that the observed increases in the efficacy of  
485 glutamatergic neurotransmission in mPFC-BLA projections could be specifically  
486 attributed to MIA.

487

488 We next explored synaptic expression mechanisms of MIA-triggered synaptic  
489 potentiation in mPFC-BLA projections. The observed synaptic strengthening could be  
490 due either to enhanced probability of neurotransmitter release (*Pr*) or increased  
491 responsiveness to single quanta of glutamate, or both, as well as due to increases in  
492 the number of sites of synaptic transmission (Zucker and Regehr, 2002; Tsvetkov et al.,  
493 2002; Goussakov et al., 2006; Cho et al., 2013). We found that the magnitude of the  
494 paired-pulse ratio (PPR) at the mPFC-BLA synapses, a commonly used measure of  
495 presynaptic function (*Pr*, specifically), was identical in slices from all experimental  
496 groups, indicating that *Pr* at prefrontal glutamatergic inputs to BLA remained unaffected  
497 by MIA, PIA or MIA+PIA (Fig. 4E,F; two-way ANOVA, Poly I:C,  $F_{(1,89)} = 0.99$ ,  $p = 0.321$ ;  
498 LPS,  $F_{(1,89)} = 0.483$ ,  $p = 0.489$ ; interaction,  $F_{(1,89)} = 0.04$ ,  $p = 0.852$ ). To address the  
499 possibility that immunoactivation could be associated with postsynaptic modifications at  
500 glutamatergic inputs to BLA neurons, we recorded and analyzed spontaneous EPSCs

501 (sEPSCs), which reflect synaptic responses to single quanta of glutamate (Li et al.,  
502 2013) (Fig. 4G-I). The sEPSCs were recorded at a holding potential of -80 mV in the  
503 presence of bicuculline (30  $\mu$ M). Consistent with the potentiating effect of MIA on  
504 evoked, light-induced synaptic responses, the amplitude of sEPSPs was enhanced in  
505 Poly I:C\_Veh and Poly I:C\_LPS groups relative to control Veh-Veh mice (Fig. 4J; two-  
506 way ANOVA, Poly I:C,  $F_{(1,32)} = 17.523$ ,  $p < 0.001$ ; LPS,  $F_{(1,32)} = 0.292$ ,  $p = 0.593$ ;  
507 interaction,  $F_{(1,32)} = 0.251$ ,  $p = 0.62$ ; post-hoc *Bonferroni's* test:  $p = 0.007$  for Veh\_Veh  
508 versus Poly I:C\_Veh and  $p = 0.002$  for Veh\_Veh versus Poly I:C\_LPS). However, the  
509 frequency of sEPSC, reflecting presynaptic function, was not altered (Fig. 4K; two-way  
510 ANOVA, Poly I:C,  $F_{(1,32)} = 0.02$ ,  $p = 0.887$ ; LPS,  $F_{(1,32)} = 0.361$ ,  $p = 0.552$ ; interaction,  
511  $F_{(1,32)} = 0.187$ ,  $p = 0.669$ ). Together, these results suggest that potentiation of  
512 glutamatergic synaptic transmission in mPFC-BLA projections in Poly I:C\_Veh and Poly  
513 I:C\_LPS groups may be postsynaptically regulated.

514

515 Notably, Sholl analyses of neuronal structure in neurobiotin-filled BLA principal neurons  
516 in fixed tissue sections showed that immune activation was associated with  
517 morphological changes. Thus, the averaged soma size (area) was increased in Poly  
518 I:C\_LPS-treated mice (Fig. 5A,B; soma size: two-way ANOVA, Poly I:C,  $F_{(1,28)} = 2.553$ ,  
519  $p = 0.121$ ; LPS,  $F_{(1,28)} = 11.417$ ,  $p = 0.002$ ; interaction,  $F_{(1,28)} = 0.085$ ,  $p = 0.773$ , post-  
520 hoc *Bonferroni's* test:  $p = 0.005$  for Veh\_Veh vs Poly IC\_LPS). We detected the main  
521 effect of LPS treatment on the number of primary dendrites (Fig. 1C; two-way ANOVA,  
522 Poly I:C,  $F_{(1,28)} = 0.914$ ,  $p = 0.347$ ; LPS,  $F_{(1,28)} = 5.264$ ,  $p = 0.029$ ; interaction,  $F_{(1,28)} =$   
523  $0.91$ ,  $p = 0.347$ ). However, post-hoc *Bonferroni's* test did not reveal statistically

524 significant differences between Veh\_Veh and Poly IC\_LPS groups ( $F_{(3,28)} = 2.364$ ,  $p =$   
525 0.092). The dendritic surface area and averaged dendritic diameter were also  
526 enhanced in Veh\_LPS and Poly I:C\_LPS groups (Fig. 5E,G), as well as the dendritic  
527 length in the Veh-LPS group (Fig. 5D), whereas the number of branch points was  
528 unaffected by immune activation (Fig. 5C,F).

529

530 **PIA selectively decreases feed-forward GABAergic inhibition in mPFC-BLA**  
531 **projections**

532 Excitatory neurotransmission in the BLA is under strong inhibitory control by local circuit  
533 GABA-releasing interneurons (Ehrlich et al., 2009). Specifically, BLA interneurons  
534 receive direct glutamatergic inputs from the mPFC, and when interneurons are driven  
535 above the AP firing threshold, this results in feed-forward inhibition of BLA principal  
536 neurons (Fig. 6A; Cho et al., 2013). We explored whether neuronal immunoactivation  
537 could affect the efficacy of feed-forward inhibition in mPFC-BLA projections, thereby  
538 modifying the firing output of BLA neurons. Consistent with previous reports, activation  
539 of mPFC projections to the BLA by pulses of blue light resulted in monosynaptic (see  
540 above) glutamatergic EPSCs in recorded neurons which were followed by GABA<sub>A</sub>  
541 receptor-mediated inhibitory postsynaptic currents (IPSCs). To record the excitatory  
542 and inhibitory responses from the same neurons in isolation, we evoked the EPSCs at a  
543 holding potential of -80 mV (close to the reversal potential for chloride-mediated  
544 GABAergic IPSCs and the IPSCs at 0 mV (the reversal potential for AMPA receptor  
545 EPSCs) (as in Cho et al., 2013) (Fig. 6B). Synaptic latencies of IPSCs were ~2 times  
546 longer than those of the EPSCs, consistent with the disynaptic nature of inhibitory

547 responses (Fig. 5B; Student's two-tailed paired  $t$ -test,  $t_{(14)} = 5.296$ ,  $p < 0.001$  for the  
548 comparison between synaptic latencies of EPSCs and IPSCs). The IPSCs at 0 mV  
549 were completely blocked by bicuculline (30  $\mu$ M), confirming that IPSCs were mediated  
550 by activation of GABA<sub>A</sub> receptors and were not contaminated by EPSCs at this holding  
551 potential (Fig. 6C). Conversely, the EPSCs at -80 mV were suppressed by  
552 AMPA/kainate and N-methyl-D-aspartate (NMDA) receptor antagonists (10  $\mu$ M NBQX  
553 and 50  $\mu$ M D-AP5, respectively), when the antagonists were applied together (Fig. 6D).  
554 GABA<sub>A</sub>R-IPSCs were also completely blocked by the application of NBQX and D-AP5,  
555 confirming that they were disynaptic, mediating feed-forward inhibition of BLA neurons  
556 (Fig. 6D).

557

558 To examine the effects of immunoactivation on feed-forward inhibition in mPFC-BLA  
559 projections, we first recorded photostimulation-induced glutamatergic EPSCs at -80 mV  
560 and then GABAergic IPSCs at 0 mV (see above) from the same neurons in the BLA (Fig.  
561 6E) in control and treated mice, and calculated IPSC/EPSC amplitude ratios in all  
562 experimental groups. We found that these ratios were significantly reduced in slices  
563 from Veh\_LPS and Poly I:C\_LPS groups compared to control Veh\_Veh animals (Fig.  
564 6F; two-way ANOVA, Poly I:C,  $F_{(1,67)} = 0.004$ ,  $p = 0.95$ ; LPS,  $F_{(1,67)} = 14.598$ ,  $p < 0.001$ ;  
565 interaction,  $F_{(1,67)} = 0.148$ ,  $p = 0.702$ ; post-hoc *Bonferroni's* test:  $p = 0.044$  for Veh\_Veh  
566 versus Veh\_LPS and  $p = 0.027$  for Veh\_Veh versus Poly I:C\_LPS). However,  
567 IPSC/EPSC amplitude ratios were not altered in the Poly I:C\_Veh group. Notably,  
568 neither MIA, PIA nor MIA+PIA had effects on the latencies of synaptic responses in  
569 mPFC inputs to the BLA (Fig. 6G; EPSC latencies: two-way ANOVA, Poly I:C,  $F_{(1,67)} =$

570 1.733,  $p = 0.193$ ; LPS,  $F_{(1,67)} = 1.245$ ,  $p = 0.269$ ; interaction,  $F_{(1,67)} = 1.522$ ,  $p = 0.222$ ;  
571 IPSC latencies: two-way ANOVA, Poly I:C,  $F_{(1,67)} = 2.538$ ,  $p = 0.116$ ; LPS,  $F_{(1,67)} = 0.402$ ,  
572  $p = 0.528$ ; interaction,  $F_{(1,67)} = 0.519$ ,  $p = 0.474$ ). Considered together with the fact that  
573 the efficacy of glutamatergic synaptic transmission was unaffected in Veh\_LPS mice  
574 (Fig. 4C,D), these findings suggest that PIA, but not MIA, led to decreased feed-forward  
575 inhibition, thus shifting the balance between inhibition and excitation in mPFC-BLA  
576 projections toward a greater functional efficiency of excitation. Therefore, it appears  
577 that MIA and PIA may have distinct cellular targets in the BLA.

578

579 **Neuroinflammation-induced synaptic modifications in mPFC-BLA projections**  
580 **lead to increased firing output of BLA neurons**

581 To explore the functional consequences of MIA-induced strengthening of glutamatergic  
582 synapses and PIA-induced suppression of feed-forward GABAergic inhibitory responses  
583 in prefrontal projections to the BLA, we tested the effects of immunoactivation on the  
584 probability of synaptically-driven spiking at the studied pathways (Riccio et al., 2009;  
585 Cho et al., 2012; Cho et al., 2013). We induced extracellular synaptically-triggered  
586 spikes with photostimuli of increasing intensity (ranging from 0.5 to 10.2 mW/mm<sup>2</sup>) and  
587 recorded them in BLA neurons in a cell-attached patch configuration (Fig. 7A,B). Under  
588 these recording conditions, we minimized the contribution of voltage errors, which might  
589 be prominent for synaptic responses exceeding 1 nA in amplitude (see Fig. 4C), and  
590 avoided the potential problems associated with prolonged whole-cell recordings, which  
591 can disturb the intracellular milieu thus possibly affecting the properties of recorded  
592 neurons (Cho et al., 2011). Notably, the probability of AP generation was dramatically

593 increased when the GABA<sub>A</sub> receptor antagonist bicuculline (30 μM) was added to the  
594 external medium (Fig. 7C,D; two-way ANOVA,  $F_{(1,84)} = 14.169$ ,  $p < 0.001$ ), providing  
595 evidence that synaptically-driven spike output of BLA neurons is under inhibitory control.  
596 We then compared the average number of extracellular spikes triggered in BLA neurons  
597 by single pulses of light of increasing intensity delivered to the ChR2-expressing mPFC  
598 fibers. We found that the probability of neuronal firing induced by synaptic activation  
599 was increased in slices from the Veh\_LPS group only (relative to the control Veh\_Veh  
600 group) (Fig. 7E,F; three-way ANOVA (Poly I:C x LPS x light power density), Poly I:C,  
601  $F_{(1,442)} = 23.474$ ,  $p < 0.001$ ; LPS,  $F_{(1,442)} = 34.994$ ,  $p < 0.001$ ; interaction,  $F_{(1,442)} = 1.027$ ,  
602  $p = 0.401$ ; post-hoc *Bonferroni's* multiple comparisons:  $p < 0.001$  for Veh\_Veh versus  
603 Veh\_LPS, whereas there was no effect of the treatments on spike output of BLA  
604 neurons in Poly I:C\_Veh or Poly I:C\_LPS groups.

605

606 Considered together, our findings provide evidence that neuroinflammation-associated  
607 synaptic modifications are functionally relevant, modifying the signal flow in mPFC-BLA  
608 circuits, and that the various manipulations (MIA, PIA, MIA+PIA) can be distinguished  
609 from each other using our methodologies, enabling the development of a model that  
610 depicts the specific effects of each process (Fig. 8).

611

## 612 **DISCUSSION**

613 Our studies provide evidence that MIA and PIA could have distinct cellular targets in the  
614 brain. Specifically, our MIA regimen (prenatal PolyI:C) led to the strengthening of  
615 monosynaptic glutamatergic inputs of the mPFC-arising afferents to principal neurons in

616 the BLA, whereas our PIA regimen (postnatal LPS) suppressed feed-forward GABA<sub>A</sub>R-  
617 mediated inhibition of BLA neurons by local circuit interneurons. The resulting shift in  
618 the balance between excitation and inhibition in mPFC-BLA projections, enhancing the  
619 functional efficiency of excitatory prefrontal inputs, translated into the increased firing of  
620 BLA neurons. These physiological alterations were accompanied by increases in  
621 anxiety-like behavior and decreases in social interactions, in groups in which mice had  
622 received LPS treatment (Veh\_LPS and Poly I:C\_LPS). Conversely, systemic  
623 neuroinflammation has been shown previously to result in increased neuronal activity  
624 within the AMG, which was correlated with increases in anxiety-like behavior (Engler et  
625 al., 2011). The fact that all of the immune-activating treatments produced distinct  
626 physiological consequences, even in the absence of a significant change in behavior  
627 (e.g., Poly I:C\_Veh mice), suggest a potentially higher sensitivity of the  
628 electrophysiological techniques in detecting effects that might be below the threshold for  
629 significantly altering behavioral endpoints.

630

631 Our results enable the development of a circuit model that captures the unique  
632 “physiological signature” of each treatment. Mechanistically, in the offspring of Poly I:C-  
633 treated dams (Poly I:C\_Veh group), the efficacy of glutamatergic synaptic transmission  
634 in mPFC projections to both BLA principal neurons (PN) and BLA interneurons (IN) was  
635 proportionally increased (shown as thicker red lines in Fig. 8B), reflected in  
636 proportionally increased amplitudes of EPSCs and IPSCs. The proportionality of the  
637 effect of MIA on EPSCs and IPSCs is supported by the finding that the IPSC/EPSC  
638 amplitude ratio in slices from these mice was unaffected relative to control Veh\_Veh

639 mice. Consistent with this, the spike output of BLA neurons in response to activation of  
640 mPFC afferents remained unchanged. Postnatal immunoactivation alone (VEH\_LPS  
641 group) did not affect synaptic efficacy at glutamatergic mPFC inputs to the BLA, but it  
642 was associated with decreases in the amplitude of feed-forward IN-mediated IPSCs  
643 (represented as a thinner blue line in the diagram in Fig. 8C). The resulting decreases  
644 in the IPSC/EPSC amplitude ratio led to the increased functional efficiency of  
645 neurotransmission in the mPFC-BLA projections, translating into the increased spike  
646 output of BLA PNs. In mice from the Poly I:C\_LPS group, the BLA spike output appears  
647 to be determined by complex interactions between the effects of MIA (increased  
648 synaptic strength at both glutamatergic and GABAergic inputs to BLA PNs) and PIA-  
649 induced decreases in inhibition. Although the opposing effects of MIA and PIA on feed-  
650 forward inhibition partially compensate each other, the IPSC/EPSC amplitude ratio was  
651 still decreased relative to control animals (Fig. 8D). However, this shift toward a greater  
652 functional efficiency of excitation in the Poly I:C\_LPS group was insufficient to affect the  
653 spike output of BLA neurons in mPFC-BLA projections. Regardless, each of the three  
654 treatments produces a unique signature that can be differentiated from the others.

655

656 Our finding that the altered signal flow in the mPFC-amygdala pathways may result in  
657 enhanced anxiety and decreased social interactions is consistent with previously  
658 published observations implicating both the mPFC (Elliott et al., 2016; Felix-Ortiz et al.,  
659 2016; Vila-Verde et al., 2016) and BLA complex (Sanders et al., 1995; Frankland et al.,  
660 1997; Perez de la Mora et al., 2006) in control of innate fear and anxiety responses. In  
661 addition, we recently reported evidence that, among other mechanisms, the activation of

662 the BLA complex mediates anxiogenesis (Riccio et al., 2014). Specifically, we found  
663 that the knockdown of the Transient Receptor Potential Channel Subunit 4 (TRPC4)  
664 subunit, abundantly expressed in brain areas controlling innate fear responses in the  
665 normal mouse brain, in the lateral amygdala resulted in suppressed innate fear  
666 responses as quantified with anxiety-probing behavioral tests. Our present results link  
667 together these previously disparate observations, highlighting the role of mPFC-BLA  
668 projections in control of anxiety-like behaviors, which are frequently co-morbid with ASD  
669 (South et al., 2017). Considering that it has been shown that MIA alone and PIA alone  
670 can each produce behavioral signs in mice that resemble the core features of ASDs  
671 (e.g., aberrant social interactions, communication deficits, and increases in stereotyped  
672 behaviors) (Smith et al., 2007; Custódio et al., 2017), our data raise the possibility that  
673 mPFC-BLA functional interactions could be affected in humans with ASD.

674

675 It is important to emphasize that our studies characterize the effects of using Poly I:C as  
676 the trigger for MIA and LPS as the trigger for PIA. We selected this order to  
677 approximate the human condition, where postnatal bacterial infections (modeled by LPS)  
678 are highly prevalent (Bilbo et al., 2009). In addition, this order of treatment matches well  
679 with models that describe the putative time course of TLR3 (the receptor at which Poly  
680 I:C acts) and TLR4 (the receptor at which LPS acts) expression (Barak et al., 2014).  
681 Other permutations of this treatment regimen may yield different outcomes.

682

683 The mechanisms we describe here could contribute to the behavioral manifestations of  
684 ASD, providing evidence that the development of ASD may implicate dysregulation of

685 the functional connectivity between distinct brain regions involved in control of specific  
686 behavioral mechanisms (Markram and Markram, 2010; Monk et al., 2010; Rudie et al.,  
687 2012). More generally, our work lends support to a theory that the development of ASD  
688 may be associated with the excitation/inhibition imbalance in the brain leading to  
689 increased excitability of relevant neural circuits (Hussman, 2001; Rubenstein and  
690 Merzenich, 2003; Nelson and Valakh, 2015; Canetta et al., 2016; Lee et al., 2017).  
691 Future studies will be needed to identify molecular pathways implicated in  
692 neuroinflammation-induced synaptic changes in the mPFC-BLA circuits, and to  
693 determine if there might be sex differences that contribute to the prevalence of  
694 conditions such as ASD (Baron-Cohen et al., 2005; Werling and Geschwind, 2013).

695

#### 696 REFERENCES

697 Abrahams BS, Geschwind DH (2008) Advances in autism genetics: on the threshold of  
698 a new neurobiology. *Nat Rev Genet* 9:341-355.

699 Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, Parner  
700 ET (2010) Maternal infection requiring hospitalization during pregnancy and autism  
701 spectrum disorders. *J Autism Dev Disord* 40:1423-1430.

702 Bagot RC, Parise EM, Peña CJ, Zhang HX, Maze I, Chaudhury D, Persaud B, Cachope  
703 R, Bolaños-Guzmán CA, Cheer JF, Deisseroth K, Han MH, Nestler EJ (2015) Ventral  
704 hippocampal afferents to the nucleus accumbens regulate susceptibility to depression.  
705 *Nat Commun* 6:7626.

706

707 Barak B, Feldman N, Okun E (2014) Toll-like receptors as developmental tools that  
708 regulate neurogenesis during development: an update. *Front Neurosci* 8:272.

709

710 Baron-Cohen S, Knickmeyer RC, Belmonte MK (2005) Sex differences in the brain:  
711 implications for explaining autism. *Science* 310:819-823.

712

713 Baron-Cohen S, Ring HA, Wheelwright S, Bullmore ET, Brammer MJ, Simmons A,  
714 Williams SC (1999) Social intelligence in the normal and autistic brain: an fMRI study.  
715 *Eur J Neurosci* 11:1891-1898.

716

- 717 Betancur C (2011) Etiological heterogeneity in autism spectrum disorders: more than  
718 100 genetic and genomic disorders and still counting. *Brain Res* 1380:42-77.  
719
- 720 Bilbo SD, Schwarz JM (2009) Early-Life Programming of Later-Life Brain and Behavior:  
721 A Critical Role for the Immune System. *Front Behav Neurosci* 3:14.  
722
- 723 Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005) Millisecond-timescale,  
724 genetically targeted optical control of neural activity. *Nat Neurosci* 8:1263-1268.  
725
- 726 Britton DR, Britton KT (1981) A sensitive open field measure of anxiolytic drug activity.  
727 *Pharmacol Biochem Behav* 15:577-582.  
728
- 729 Canetta S, Bolkan S, Padilla-Coreano N, Song LJ, Sahn R, Harrison NL, Gordon JA,  
730 Brown A, Kellendonk C (2016) Maternal immune activation leads to selective functional  
731 deficits in offspring parvalbumin interneurons. *Mol Psychiatry* 21:956-68.
- 732 Cho JH, Bayazitov IT, Meloni EG, Myers KM, Carlezon WA Jr, Zakharenko SS,  
733 Bolshakov VY (2011) Coactivation of thalamic and cortical pathways induces input  
734 timing-dependent plasticity in amygdala. *Nat Neurosci* 15:113-122.  
735
- 736 Cho JH, Zushida K, Shumyatsky GP, Carlezon WA Jr, Meloni EG, Bolshakov VY (2012)  
737 Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed  
738 potentiation in the intra-amygdala circuit. *J Neurosci* 32:14165-14177.  
739
- 740 Cho JH, Deisseroth K, Bolshakov VY (2013) Synaptic encoding of fear extinction in  
741 mPFC-amygdala circuits. *Neuron* 80:1491-1507.  
742
- 743 Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffler CA, Littman DR, Huh JR  
744 (2016) The maternal interleukin-17a pathway in mice promotes autism-like phenotypes  
745 in offspring. *Science* 351:933-939
- 746 Custódio CS, Mello BSF, Filho AJMC, de Carvalho Lima CN, Cordeiro RC, Miyajima F,  
747 Réus GZ, Vasconcelos SMM, Barichello T, Quevedo J, de Oliveira AC, de Lucena DF,  
748 Macedo DS (2017) Neonatal immune challenge with lipopolysaccharide triggers long-  
749 lasting sex- and age-related behavioral and immune/neurotrophic alterations in mice:  
750 relevance to autism spectrum disorders. *Mol Neurobiol* 54:Epub ahead of print.
- 751 Ehrlich I, Humeau Y, Grenier F, Ciochi S, Herry C, Lüthi A (2009) Amygdala inhibitory  
752 circuits and the control of fear memory. *Neuron* 62:757-771.  
753
- 754 Elliott E, Manashirov S, Zwang R, Gil S, Tsoory M, Shemesh Y, Chen A (2016) Dnmt3a  
755 in the medial prefrontal cortex regulates anxiety-like behavior in adult mice. *J Neurosci*  
756 36:730-740.  
757

- 758 Engler H, Doenlen R, Engler A, Riether C, Prager G, Niemi MB, Pacheco-López G,  
759 Krügel U, Schedlowski M (2011) Acute amygdaloid response to systemic inflammation.  
760 *Brain Behav Immun* 25:1384-1392.
- 761  
762 File SE (1985) What can be learned from the effects of benzodiazepines on exploratory  
763 behavior? *Neurosci Biobehav Rev* 9:45-54.
- 764  
765 Felix-Ortiz AC, Burgos-Robles A, Bhagat ND, Leppla CA, Tye KM (2016) Bidirectional  
766 modulation of anxiety-related and social behaviors by amygdala projections to the  
767 medial prefrontal cortex. *Neuroscience* 321: 197-209.
- 768  
769 Frankland PW, Josselyn SA, Bradwejn J, Vaccarino FJ, Yeomans JS (1997) Activation  
770 of amygdala cholecystokininB receptors potentiates the acoustic startle response in the  
771 rat. *J Neurosci* 17:1838-1847.
- 772  
773 Franklin K, Paxinos G (2007) *The Mouse Brain in Stereotaxic Coordinates*. San Diego,  
774 California: Academic Press.
- 775  
776 Gentet LJ, Stuart GJ, Clements JD (2000) Direct measurement of specific membrane  
777 capacitance in neurons. *Biophys J* 79:314-320.
- 778  
779 Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R, Winter C, Riva MA,  
780 Mortensen PB, Feldon J, Schedlowski M, Meyer U (2013) Stress in puberty unmasks  
781 latent neuropathological consequences of prenatal immune activation in mice. *Science*  
339:1095-1099.
- 782  
783 Golden SA, Covington HE 3rd, Berton O, Russo SJ (2011) A standardized protocol for  
784 repeated social defeat stress in mice. *Nat Protoc* 6:1183-1191
- 785  
786 Goussakov I, Chartoff EH, Tsvetkov E, Gerety LP, Meloni EG, Carlezon WA Jr,  
787 Bolshakov VY (2006) LTP in the lateral amygdala during cocaine withdrawal. *Eur J*  
*Neurosci* 23:239-250.
- 788  
789 Hadjkacem I, Ayadi H, Turki M, Yaich S, Khemekhem K, Walha A, Cherif L, Moalla Y,  
790 Ghribi F (2016) Prenatal, perinatal and postnatal factors associated with autism  
791 spectrum disorder. *J Pediatr* 92:595-601.
- 792  
793 Harvey L, Boksa P. (2012) Prenatal and postnatal animal models of immune activation:  
794 relevance to a range of neurodevelopmental disorders. *Dev Neurobiol* 72: 1335-1348.
- 795  
796 Hussman JP (2001) Suppressed GABAergic inhibition as a common factor in suspected  
797 etiologies of autism. *J Autism Dev Disord* 31:247-248.
- 798  
799 Hübner C, Bosch D, Gall A, Lüthi A, Ehrlich I (2014) Ex vivo dissection of  
800 optogenetically activated mPFC and hippocampal inputs to neurons in the basolateral  
amygdala: implications for fear and emotional memory. *Front Behav Neurosci* 8:64.

- 801  
802 Kawai T, Akira S (2008) Toll-like receptor and RIG-I-like receptor signaling. *Ann NY*  
803 *Acad Sci* 1143:1-20.
- 804  
805 Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA Toovey S,  
806 Prinssen EP (2014) Maternal immune activation and abnormal brain development  
807 across CNS disorders. *Nat Rev Neurol* 10:643-660.
- 808  
809 Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, Manalastas A, Hilfiker  
810 M, Pfister S, Schwerdel C, Riether C, Meyer U, Knuesel I (2012) Systemic immune  
811 challenges trigger and drive Alzheimer-like neuropathology in mice. *J*  
812 *Neuroinflammation* 9:151.
- 813  
814 LeDoux JE (2000) Emotion circuits in the brain. *Annu Rev Neurosci* 23:155-184.
- 815  
816 Lee E, Lee J, Kim E (2017) Excitation/inhibition imbalance in animal models of autism  
817 spectrum disorders. *Biol Psychiatry* 81:838-847.
- 818  
819 Lezak KR, Missig G, Carlezon WA Jr. (2017) Behavioral methods to study anxiety in  
820 rodents. *Dialogues Clin Neurosci* 19:79-89.
- 821  
822 Li Y, Meloni EG, Carlezon WA Jr, Milad MR, Pitman RK, Nader K, Bolshakov VY (2013)  
823 Learning and reconsolidation implicate different synaptic mechanisms. *Proc Natl Acad*  
824 *Sci USA* 110:4798-4803.
- 825  
826 Lombardo MV, Moon HM, Su J, Palmer TD, Courchesne E, Pramparo T (2017)  
827 Maternal immune activation dysregulation of the fetal brain transcriptome and relevance  
828 to the pathophysiology of autism spectrum disorder. *Mol Psychiatry* (Epub ahead of  
print).
- 829  
830 Luchkina NV, Bolshakov VY (2017) Diminishing fear: Optogenetic approach toward  
831 understanding neural circuits of fear control. *Pharmacol Biochem Behav* (Epub ahead of  
832 print).
- 833  
834 Maren S, Quirk GJ (2004) Neuronal signalling of fear memory. *Nat Rev Neurosci* 5:  
835 844-852.
- 836  
837 Markram K, Markram H (2010) The intense world theory - a unifying theory of the  
838 neurobiology of autism. *Front Hum Neurosci* 4:224.
- 839  
840 McDougale CJ, Landino SM, Vahabzadeh A, O'Rourke J, Zurcher NR, Finger BC,  
841 Palumbo ML, Helt J, Mullett JE, Hooker JM, Carlezon WA Jr (2015) Toward an immune-  
842 mediated subtype of autism spectrum disorder. *Brain Res* 1617:72-92.
- 843  
844 Meltzer A, Van de Water J (2017) The role of the immune system in autism spectrum  
disorder. *Neuropsychopharmacology* 42:284-298.

- 845  
846 Miller AH, Haroon E, Felger JC (2017) The immunology of behavior-exploring the role of  
847 the immune system in brain health and illness. *Neuropsychopharmacology* 42:1-4.  
848
- 849 Monk CS, Weng SJ, Wiggins JL, Kurapati N, Louro HM, Carrasco M, Maslowsky J, Risi  
850 S, Lord C (2010) Neural circuitry of emotional face processing in autism spectrum  
851 disorders. *J Psychiatry Neurosci* 35:105-114.  
852
- 853 Mrozek-Budzyn D, Majewska R, Kieltyka A (2013) Prenatal, perinatal and neonatal risk  
854 factors for autism – study in Poland. *Cent Eur J Med* 8:424-430.  
855
- 856 Nelson SB, Valakh V (2015) Excitatory/Inhibitory balance and circuit homeostasis in  
857 autism spectrum disorders. *Neuron* 87:684-698.  
858
- 859 Onore C, Careaga M, Ashwood P (2012) The role of immune dysfunction in the  
860 pathophysiology of autism. *Brain Behav Immun* 26:383-392.  
861
- 862 O'Roak BJ et al. (2012) Multiplex targeted sequencing identifies recurrently mutated  
863 genes in autism spectrum disorders. *Science* 338:1619-1622.  
864
- 865 Pape HC, Pare D (2010) Plastic synaptic networks of the amygdala for the acquisition,  
866 expression, and extinction of conditioned fear. *Physiol Rev* 90:419-463.  
867
- 868 Patel S, Masi A, Dale RC, Whitehouse AJO, Pokorski I, Alvares GA, Hickie IB, Breen E,  
869 Guastella AJ (2017) Social impairments in autism spectrum disorder are related to  
870 maternal immune history profile. *Mol Psychiatry* (Epub ahead of print).  
871
- 872 Patterson PH (2009) Immune involvement in schizophrenia and autism: etiology,  
873 pathology and animal models. *Behav Brain Res* 204:313-321.  
874
- 875 Petreanu L, Mao T, Sternson SM, Svoboda K (2009) The subcellular organization of  
876 neocortical excitatory connections. *Nature* 457:1142-1145.  
877
- 878 Perez de la Mora M, Lara-Garcia D, Jacobsen KX, Vazquez-Garcia M, Crespo-Ramirez  
879 M, Flores-Gracia C, Escamilla-Marvan E, Fuxe K (2006) Anxiolytic-like effects of the  
880 selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid  
881 microinjection in three different non-conditioned rat models of anxiety. *Eur J Neurosci*  
882 23:2749-2759.  
883
- 884 Reisinger S, Khan D, Kong E, Berger A, Pollak A, Pollak DD (2015) The poly(I:C)-  
885 induced maternal immune activation model in preclinical neuropsychiatric drug  
886 discovery. *Pharmacol Ther* 149:213-226.  
887
- 888 Riccio A, Li Y, Moon J, Kim KS, Smith KS, Rudolph U, Gapon S, Yao GL, Tsvetkov E,  
889 Rodig SJ, Van't Veer A, Meloni EG, Carlezon WA Jr, Bolshakov VY, Clapham DE (2009)

- 890 Essential role for TRPC5 in amygdala function and fear-related behavior. *Cell* 137:761-  
891 772.
- 892
- 893 Riccio A, Li Y, Tsvetkov E, Gapon S, Yao GL, Smith KS, Engin E, Rudolph U,  
894 Bolshakov VY, Clapham DE (2014) Decreased anxiety-like behavior and Gαq/11-  
895 dependent responses in the amygdala of mice lacking TRPC4 channels. *J Neurosci*  
896 34:3653-3667.
- 897
- 898 Rinaldi T, Perrodin C, Markram H (2008) Hyper-connectivity and hyper-plasticity in the  
899 medial prefrontal cortex in the valproic Acid animal model of autism. *Front Neural*  
900 *Circuits* 2:4.
- 901
- 902 Rubenstein JL, Merzenich MM (2003) Model of autism: increased ratio of  
903 excitation/inhibition in key neural systems. *Genes Brain Behav* 2:255-267.
- 904
- 905 Rudie JD, Shehzad Z, Hernandez LM, Colich NL, Bookheimer SY, Iacoboni M, Dapretto  
906 M (2012) Reduced functional integration and segregation of distributed neural systems  
907 underlying social and emotional information processing in autism spectrum disorders.  
908 *Cereb Cortex* 22:1025-1037.
- 909
- 910 Sah P, Faber ESL, Lopez De Armentia M, Power J (2003) The amygdaloid complex:  
911 anatomy and physiology. *Physiol Rev* 83:803-834.
- 912
- 913 Sanders SK, Shekhar A (1995) Regulation of anxiety by GABAA receptors in the rat  
914 amygdala. *Pharmacol Biochem Behav* 52:701-706.
- 915
- 916 Sangha S, Greba Q, Robinson PD, Ballentine SA, Howland JG (2014) Heightened fear  
917 in response to a safety cue and extinguished fear cue in a rat model of maternal  
918 immune activation. *Front Behav Neurosci* 8:168.
- 919
- 920 Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ (2013) Brain  
921 development in rodents and humans: Identifying benchmarks of maturation and  
922 vulnerability to injury across species. *Prog Neurobiol* 106-107:1-16.
- 923
- 924 Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of  
925 the cat. *J Anat* 87:387-406.
- 926
- 927 Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal immune activation  
928 alters fetal brain development through interleukin-6. *J Neurosci* 27:10695-10702.
- 929
- 930 South M, Rodgers J (2017) Sensory, emotional and cognitive contributions to anxiety in  
931 autism spectrum disorders. *Front Hum Neurosci* 11:20.
- 932
- 933 Strobel C, Marek R, Gooch HM, Sullivan RK, Sah P (2015) Prefrontal and auditory input  
934 to intercalated neurons of the amygdala. *Cell Rep* 10:1435-1442.
- 935

936 Sui L, Chen M (2012) Prenatal exposure to valproic acid enhances synaptic plasticity in  
937 the medial prefrontal cortex and fear memories. *Brain Res Bull* 87:556-563.

938

939 Talkowski ME, Minikel EV, Gusella JF (2014) Autism spectrum disorder genetics:  
940 diverse genes with diverse clinical outcomes. *Harv Rev Psychiatry* 22:65-75.

941 Testa-Silva G, Loebel A, Giugliano M, de Kock CP, Mansvelder HD, Meredith RM  
942 (2012) Hyperconnectivity and slow synapses during early development of medial  
943 prefrontal cortex in a mouse model for mental retardation and autism. *Cereb Cortex* 22:  
944 1333-1342.

945 Tsvetkov E, Carlezon WA, Benes FM, Kandel ER, Bolshakov VY (2002) Fear  
946 conditioning occludes LTP-induced presynaptic enhancement of synaptic transmission  
947 in the cortical pathway to the lateral amygdala. *Neuron* 34:289-300.

948

949 Vila-Verde C, Marinho AL, Lisboa SF, Guimarães FS (2016) Nitric oxide in the prelimbic  
950 medial prefrontal cortex is involved in the anxiogenic-like effect induced by acute  
951 restraint stress in rats. *Neuroscience* 320:30-42.

952

953 Werling DM, Geschwind DH (2013) Sex differences in autism spectrum disorders. *Curr*  
954 *Opin Neurol* 26:146-153.

955

956 Zerbo O, Iosif AM, Delwiche L, Walker C, Hertz-Picciotto I, Knuesel (2011) Month of  
957 conception and risk of autism. *Epidemiology* 22:469-475.

958

959 Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. *Annu Rev Physiol* 64:  
960 355-405.

961

962

### 963 **Figure Legends**

964 **Figure 1.** Immune activation is associated with activation of microglia in the BLA and

965 ASD-related behavioral dysfunctions. **A**, Experimental design (see the main text for

966 details). **B**, Confocal microscopic images showing immunohistochemical staining for

967 Ionized calcium binding adaptor molecule 1 (IBA-1), a microglial marker, in the

968 basolateral nucleus of the amygdala (BLA) in 13-week old offspring mice from different

969 experimental groups. **C**, The number of IBA-1 positive cells and immunoreactivity (IR)

970 of IBA-1 were increased in the offspring groups receiving the postnatal LPS injections,

971 indicating a robust activation of microglia ~12 weeks after the LPS injection at PND9  
972 (Veh\_Veh group:  $n = 6$  slides from 4 mice; Poly I:C\_Veh:  $n = 8$  slides from 4 mice;  
973 Veh\_LPS:  $n = 5$  slides from 3 mice; Poly I:C\_LPS:  $n = 3$  slides from 3 mice). **D**,  
974 Quantitative morphological analysis of microglia in the animal models of maternal and  
975 postnatal immunoactivation. Left, there was no difference in the soma size of microglia  
976 in the BLA between experimental groups (Veh-Veh group:  $n = 50$  from 4 mice; Poly  
977 I:C\_Veh:  $n = 59$  from 4 mice; Veh\_LPS:  $n = 93$  from 7 mice; Poly I:C\_LPS:  $n = 36$  from  
978 3 mice). Right, the groups did not differ in the number of microglial ramifications (Veh-  
979 Veh group:  $n = 50$  from 4 mice; Poly I:C\_Veh:  $n = 59$  from 4 mice; Veh\_LPS:  $n = 93$   
980 from 7 mice; Poly I:C\_LPS:  $n = 36$  from 3 mice). **E**, Results of the open field test. Left,  
981 summary plot showing the percentage of time spent in the center of the arena.  
982 Increased anxiety-like behavior (less time spent in the center) was observed in  
983 Veh\_LPS and Poly I:C\_LPS groups relative to the control Veh\_Veh group. Right, plot  
984 showing the total distance traveled during the open field test. The number of mice  
985 tested: Veh-Veh group:  $n = 28$  mice; Poly I:C\_Veh:  $n = 26$  mice; Veh\_LPS:  $n = 11$  mice;  
986 Poly I:C\_LPS:  $n = 17$  mice. **F**, Results of the social interaction test. Left, mice in  
987 Veh\_LPS and Poly I:C\_LPS groups showed impaired social behavior as they spent less  
988 time in the interaction zone with the novel conspecific mouse relative the control  
989 Veh\_Veh group. Right, distance traveled during the social interaction test. The number  
990 of mice tested: Veh-Veh group:  $n = 12$  mice; Poly I:C\_Veh:  $n = 17$  mice; Veh\_LPS:  $n =$   
991 11 mice; Poly I:C\_LPS:  $n = 18$  mice. Error bars are SEM.  
992

993 **Figure 2. Optogenetic analysis of mPFC inputs to the BLA in animal models of**  
994 **maternal and postnatal immunoactivation. A**, Experimental design for optogenetic  
995 activation of mPFC-amygdala projections. A vertical dashed line indicates location of a  
996 coronal section shown in *E* (as in Cho et al., 2013). **B**, Left, a microscopic image at the  
997 low magnification shows the expression of eYFP-ChR2 at the injection site in mPFC  
998 (green) merged with an image of fluorescent Nissl stain (red); Right: a confocal image  
999 showing expression of eYFP-ChR2 across the cell layers in the PL. PL, prelimbic  
1000 cortex; IL, infralimbic cortex; aca, anterior commissure, anterior part. **C**, Left, ChR2-  
1001 mediated currents recorded in a pyramidal neuron in layer V of mPFC were evoked by  
1002 1-s pulses of blue light (470 nm, blue horizontal bar) of increasing intensity (0.2 – 1.7  
1003 mW/mm<sup>2</sup>) in the presence of NBQX (10 μM), D-AP5 (50 μM) and bicuculline (30 μM).  
1004 Right, input-output plots of the photocurrent amplitudes as a function of the light power  
1005 densities (mW/mm<sup>2</sup>) in slices from different experimental groups (Veh\_Veh group: *n* =  
1006 21 neurons from 8 mice; Poly I:C\_Veh: *n* = 22 neurons from 9 mice; Veh\_LPS: *n* = 17  
1007 neurons from 7 mice; Poly I:C\_LPS: *n* = 23 neurons from 10 mice). Expression of ChR2  
1008 in the mPFC was not affected by immunoactivation. **D**, Left, examples of action  
1009 potentials recorded in a pyramidal neuron in layer V of mPFC triggered by trains of 1-ms  
1010 pulses of blue light at different stimulation frequencies (5 - 40 Hz, marked by vertical  
1011 blue bars for the 5 Hz stimulation) in current-clamp mode. Right, plot of AP firing  
1012 reliability at different stimulation frequencies (Veh\_Veh group: *n* = 9 neurons from 4  
1013 mice; Poly I:C\_Veh: *n* = 8 neurons from 5 mice; Veh\_LPS: *n* = 6 neurons from 4 mice;  
1014 Poly I:C\_LPS: *n* = 7 neurons from 5 mice).  
1015

1016 **Figure 3.** mPFC-amygdala synaptic connectivity and innervation patterns of the  
1017 amygdala by ChR2-expressing mPFC projection fibers. **A**, Light-evoked EPSCs  
1018 recorded in BLA principal neurons at  $-80$  mV were blocked by the AMPA/kainate  
1019 receptor antagonist NBQX ( $10$   $\mu$ M). **B**, Fractions of neurons in BLA and dITC in which  
1020 EPSCs could be observed in response to photostimulation of mPFC afferents in slices  
1021 from all groups. In these recordings, the light power density was  $10.5$  mW/mm<sup>2</sup> (BLA:  $n$   
1022 = 38 neurons from 38 recorded cells in Veh\_Veh group,  $n$  = 30 neurons from 30  
1023 recorded cells in Poly I:C\_Veh group,  $n$  = 36 neurons from 36 recorded cells in  
1024 Veh\_LPS group,  $n$  = 36 neurons from 36 recorded cells in Poly I:C\_LPS group; dITC:  $n$   
1025 = 8 neurons from 9 recorded cells in Veh\_Veh group,  $n$  = 5 neurons from 7 recorded  
1026 cells in Poly I:C\_Veh group,  $n$  = 6 neurons from 7 recorded cells in Veh\_LPS group,  $n$  =  
1027 8 neurons from 10 recorded cells in Poly I:C\_LPS group. **C**, Rescue of optogenetically-  
1028 induced and tetrodotoxin (TTX)-blocked EPSCs at mPFC(PL)-BLA projections by  
1029 aminopyridine (4-AP). Left, a graph showing the time course of changes in the EPSC  
1030 amplitude under control conditions (1), after application of TTX (2) and after the  
1031 subsequent addition of 4-AP (3). Right, EPSCs (average of 10 traces) recorded in a  
1032 BLA neuron at  $-80$  mV under different experimental conditions. EPSCs evoked by  
1033 photostimulation (with 5- ms-long pulses) of ChR2-expressing mPFC fibers were  
1034 blocked by TTX ( $1$   $\mu$ M). An addition of 4-AP ( $1$  mM) in the presence of TTX partially  
1035 rescued the EPSC (as in ref. 29;  $n$  = 3 neurons), confirming monosynaptic nature of  
1036 activated mPFC-BLA projections. **D**, Summary plot of the EPSC amplitudes in TTX only  
1037 and TTX + 4-AP. Peak amplitudes of EPSCs were normalized to the baseline

1038 EPSC recorded under control conditions. Open circles represent individual experiments  
1039 whereas closed circles show average values ( $n = 3$  neurons). **E**, Experimental design  
1040 for the analysis of mPFC- amygdala connectivity. Vertical lines indicate location of  
1041 coronal sections through the amygdala shown in **F**. **F**, Microscopic images showing  
1042 innervation of the amygdala by ChR2-eYFP expressing mPFC fibers (green) in coronal  
1043 brain sections (300  $\mu\text{m}$  in thickness) along the rostral-caudal axis. Blue fluorescence  
1044 indicates DAPI counter-stain. LA, lateral nucleus of the amygdala; BLA, the basolateral  
1045 nucleus of the amygdala; CeL, lateral division of the central nucleus of the amygdala;  
1046 CeM, medial division of the central nucleus; dITC, dorsal cluster of intercalated cells in  
1047 the amygdala. **G–I**, Mean densities of ChR2-eYFP fluorescence due to the innervation  
1048 by mPFC projections in different sections along the rostral-caudal axes in BLA (**G**), LA  
1049 (**H**) and CeA (**I**) in slices from all experimental groups (Veh\_Veh group:  $n = 16$  slides  
1050 from 6 mice; Poly I:C\_Veh:  $n = 14$  slides from 4 mice; Veh\_LPS:  $n = 18$  slides from 6  
1051 mice; Poly I:C\_LPS:  $n = 17$  slides from 6 mice).

1052

1053 **Figure 4.** Maternal immunoactivation (MIA) but not postnatal immunoactivation (PIA)  
1054 results in increased synaptic strength in glutamatergic mPFC projections to the BLA. **A**,  
1055 Experimental design for optogenetic analysis of mPFC- amygdala projections. A  
1056 vertical line indicates location of a coronal section through the amygdala shown in **B**. **B**,  
1057 Left, a confocal microscopic image showing ChR2-eYFP-expressing mPFC fibers in the  
1058 amygdala (green). Red fluorescent cells in the BLA are neurobiotin-filled neurons.  
1059 Right, a higher magnification image of the same section. **C**, EPSCs (average of five  
1060 responses) recorded in principal neurons (PN) in mPFC-BLA projections in voltage-

1061 clamp mode at a holding potential  $-80$  mV in slices from different experimental groups.  
1062 EPSCs were evoked by photostimuli of increasing intensity. **D**, Input-output plots for  
1063 peak amplitudes of EPSCs at the mPFC-BLA synapses in all experimental groups (Veh-  
1064 Veh group:  $n = 39$  neurons from 12 mice; Poly I:C\_Veh:  $n = 28$  neurons from 9 mice;  
1065 Veh\_LPS:  $n = 36$  neurons from 9 mice; Poly I:C\_LPS:  $n = 38$  neurons from 12 mice). **E**,  
1066 EPSC in BLA principal neurons were evoked by paired photostimuli (50-ms inter-pulse  
1067 interval) at the saturating photostimulation intensity ( $10.2$  mW/mm<sup>2</sup>) in slices from all  
1068 groups. **F**, There was no effect of the treatments on the PPR magnitude (Veh-Veh  
1069 group:  $n = 25$  neurons from 12 mice; Poly I:C\_Veh:  $n = 24$  neurons from 9 mice;  
1070 Veh\_LPS:  $n = 16$  neurons from 9 mice; Poly I:C\_LPS:  $n = 28$  neurons from 12 mice).  
1071 **G**, Examples of sEPSCs recorded in BLA neurons. **H** and **I**, Cumulative amplitude (**H**)  
1072 and inter-event interval (**I**) histograms of sEPSCs recorded in slices from all groups. **J**  
1073 and **K**, Summary plots of the mean sEPSC amplitude (**J**) and the frequency (**K**) in slices  
1074 from all groups (Veh\_Veh group:  $n = 10$  neurons from 5 mice; Poly I:C\_Veh:  $n = 9$   
1075 neurons from 6 mice; Veh\_LPS:  $n = 8$  neurons from 4 mice; Poly I:C\_LPS:  $n = 9$   
1076 neurons from 5 mice).

1077

1078 **Figure 5.** Sholl analysis of dendritic morphology in the BLA following immune  
1079 activation. **A**, Sholl dendritic analysis of reconstructed neurobiotin-filled BLA neurons  
1080 was performed by placing a series of concentric circles, spaced at  $30$ - $\mu$ m intervals,  
1081 centered on the soma. **B**, The average soma size estimates in all experimental groups.  
1082 There was a significant increase in the soma size in LPS-treated mice (see text for  
1083 details). **C**, Averaged number of primary dendrites in all experimental groups. **D**,

1084 Summary plot of the dendritic length as a function of the radial distance from soma by  
1085 30- $\mu\text{m}$  increments. There was a main effect of LPS on the dendritic length: three-way  
1086 ANOVA (Poly I:C x LPS x distance from soma), Poly I:C,  $F_{(1,224)} = 0.272$ ,  $p = 0.603$ ; LPS,  
1087  $F_{(1,224)} = 10.499$ ,  $p = 0.001$ ; interaction,  $F_{(7,224)} = 0.64$ ,  $p = 1.0$ ; post-hoc *Bonferonni's* test:  
1088  $p = 0.004$  for Veh\_Veh versus Veh\_LPS. **E**, Summary plot of the dendritic surface area  
1089 as a function of the radial distance from soma. There was an increase in the dendritic  
1090 surface area in Veh\_LPS and Poly I:C\_LPS groups versus Veh\_Veh group: three-way  
1091 ANOVA (Poly I:C x LPS x distance from soma), Poly I:C,  $F_{(1,224)} = 1.681$ ,  $p = 0.196$ ; LPS,  
1092  $F_{(1,224)} = 51.762$ ,  $p < 0.001$ ; interaction,  $F_{(1,224)} = 0.086$ ,  $p = 0.99$ ; post-hoc *Bonferonni's*  
1093 test:  $p < 0.001$  for both Veh\_Veh versus Veh\_LPS and Veh\_Veh versus Poly I:C\_LPS  
1094 groups. **F**, The averaged number of branch points. There was no difference in branch  
1095 point numbers between the groups: three-way ANOVA (Poly I:C x LPS x distance from  
1096 soma), Poly I:C,  $F_{(1,224)} = 2.27$ ,  $p = 0.133$ ; LPS,  $F_{(1,224)} = 0.0396$ ,  $p = 0.842$ ; interaction,  
1097  $F_{(7,224)} = 0.338$ ,  $p = 0.936$ . **G**, Averaged dendritic diameter as a function of distance  
1098 from soma. There was an increase in the averaged dendritic diameter in the Veh\_LPS  
1099 and Poly I:C\_LPS groups versus Veh\_Veh group: three-way ANOVA (Poly I:C x LPS x  
1100 distance from soma), Poly I:C,  $F_{(1,112)} = 7.5$ ,  $p = 0.007$ ; LPS,  $F_{(1,112)} = 30.197$ ,  $p < 0.001$ ;  
1101 interaction,  $F_{(3,112)} = 0.376$ ,  $p = 0.771$ ; post-hoc *Bonferonni's* simultaneous multiple  
1102 comparisons:  $p = 0.032$  for Veh\_Veh versus Veh\_LPS and  $p < 0.001$  for Veh\_Veh  
1103 group versus Poly I:C\_LPS group ). Veh-Veh group:  $n = 8$  neurons from 5 mice; Poly  
1104 I:C\_Veh :  $n = 8$  neurons from 4 mice; Veh\_LPS:  $n = 8$  neurons from 7 mice; Poly  
1105 I:C\_LPS:  $n = 8$  neurons from 6 mice.  
1106

1107 **Figure 6.** Feed-forward inhibition in the mPFC-BLA pathway is diminished in  
1108 postnatally immunoactivated mice. **A**, Experimental design for analyzing neural circuits  
1109 of feed-forward inhibition in the mPFC-BLA projections. Glutamatergic inputs to both  
1110 BLA principal neurons (PN) and interneurons (IN), activated by blue light stimulation of  
1111 mPFC fibers, were blocked by AMPA and NMDA receptor antagonists (10  $\mu$ M NBQX  
1112 and 50  $\mu$ M D-AP5, respectively). Projections from IN to PN were suppressed by the  
1113 GABA<sub>A</sub> receptor antagonist bicuculline (Bic, 30  $\mu$ M). **B**, Left, synaptic responses were  
1114 induced by photostimulation (7.4 – 10.2 mW/mm<sup>2</sup>) and recorded in BLA neurons at -80  
1115 mV (black trace, EPSC) and 0 mV (red trace, IPSC). The inset shows a delayed onset  
1116 (synaptic latency) of synaptic currents recorded at 0 mV. Right, mean synaptic  
1117 latencies of IPSCs and EPSCs. The IPSC latency (at a holding potential of 0 mV) was  
1118 much longer compared to EPSCs recorded in the same neurons at a holding potential  
1119 of -80 mV, suggesting that the IPSC is polysynaptic in nature ( $n = 10$  neurons from 3  
1120 mice). **C**, IPSCs at a holding potential of 0 mV were completely blocked by the GABA<sub>A</sub>  
1121 receptor antagonist bicuculline (30  $\mu$ M). **D**, Both EPSCs and IPSCs (recorded in BLA  
1122 principal neurons at -80 mV or 0 mV, respectively) were completely blocked by NBQX  
1123 (10  $\mu$ M) and D-AP5 (50  $\mu$ M), confirming that the IPSCs, mediated by activation of local  
1124 circuit interneurons, are polysynaptic in origin and triggered by glutamatergic mPFC  
1125 inputs to IN. **E**, EPSCs and IPSCs (averages of 10 traces) recorded in the same  
1126 neurons in slices from all experimental groups. IPSCs were normalized to the mean  
1127 amplitude of the EPSC at a holding potential of -80 mV to allow the comparison of  
1128 changes in the IPSC amplitude between the groups. **F**, The IPSC/EPSC amplitude ratio  
1129 was decreased in Veh\_LPS and Poly I:C\_LPS groups, indicating an effect of PIA on the

1130 balance between excitation and inhibition in mPFC-BLA projections (Veh\_Veh group:  $n$   
1131 = 17 neurons from 7 mice; Poly I:C\_Veh:  $n$  = 18 neurons from 9 mice; Veh\_LPS:  $n$  = 13  
1132 neurons from 5 mice; Poly I:C\_LPS:  $n$  = 23 neurons from 11 mice). **G**,  
1133 Immunoactivation had no effect on the latencies of EPSCs or IPSCs in mPFC-BLA  
1134 projections (Veh\_Veh group:  $n$  = 17 neurons from 7 mice; Poly I:C\_Veh:  $n$  = 18 neurons  
1135 from 9 mice; Veh\_LPS:  $n$  = 13 neurons from 5 mice; Poly I:C\_LPS:  $n$  = 23 neurons from  
1136 11 mice).

1137

1138 **Figure 7.** Neuroinflammation is associated with the increased probability of  
1139 synaptically-driven spike firing in the mPFC-BLA pathway. **A**, Experimental design for  
1140 recording of synaptically-driven extracellular spikes in BLA principal neurons in  
1141 response to photostimulation of mPFC fibers. **B**, Left, superimposed synaptic  
1142 responses (extracellular spikes) recorded in a BLA principal neuron evoked by  
1143 photostimulation of Chr2-expressing mPFC fibers in a cell-attached patch  
1144 configuration. Right, recordings under current clamp conditions from the same neuron  
1145 after establishing a whole-cell recording configuration. **C**, Examples of responses  
1146 (extracellular spikes recorded in a cell-attached patch configuration) in BLA neurons to  
1147 light pulses of increasing intensity under control conditions (left) and in the presence of  
1148 the GABA<sub>A</sub> receptor antagonist bicuculline (30  $\mu$ M, right). **D**, The number of spikes in  
1149 response to presynaptic photostimulation was increased significantly in the presence of  
1150 the GABA<sub>A</sub> receptor antagonist bicuculline (30  $\mu$ M) in the external medium (control:  $n$  =  
1151 10 neurons from 3 mice; bicuculline:  $n$  = 6 neurons from 3 mice). **E**, Examples of  
1152 synaptically-driven spikes in BLA principal neurons in slices from different groups of

1153 mice. **F**, Summary input-output plots for synaptically-driven spikes in BLA neurons in all  
1154 experimental groups (Veh\_Veh group:  $n = 22$  neurons from 7 mice; Poly I:C\_Veh:  $n =$   
1155 13 neurons from 5 mice; Veh\_LPS:  $n = 21$  neurons from 5 mice; Poly I:C\_LPS:  $n = 22$   
1156 neurons from 7 mice).

1157

1158 **Figure 8.** Functional alterations in the mPFC-BLA circuits associated with maternal and  
1159 postnatal immunoactivation. **A–D**, Left in each panel, diagrams illustrate the signal flow  
1160 in the mPFC-BLA pathways in mice from all experimental groups. Glutamatergic (red  
1161 lines) mPFC projections form excitatory synapses on BLA principal neurons (PNs) as  
1162 well as on the local circuit interneurons (INs). Interneurons form inhibitory synapses  
1163 (blue line) on PN, and thus provide strong feed-forward inhibition in the mPFC-BLA  
1164 pathway. PNs in the BLA, when driven to the AP threshold, send information (red line)  
1165 to the downstream structures, including the central nucleus of the amygdala (CeA), bed  
1166 nucleus of the stria terminalis (BNST), striatum, and cortical areas. Right, activation of  
1167 mPFC inputs to BLA PNs and INs results in generation of monosynaptic EPSCs (black  
1168 trace) and disynaptic IPSCs (blue trace), which could be recorded in BLA PNs at  
1169 holding potentials of  $-80$  mV or  $0$  mV, respectively. Changes in the thickness of lines  
1170 indicate a change in synaptic efficacy. See Discussion for the additional detailed  
1171 interpretation of experimental findings.

1172

1173 **Table 1.** Summary table of passive membrane properties determined in current-clamp  
1174 recordings from principal neurons in slices of the BLA from different experimental  
1175 groups of mice. The membrane capacitance ( $C_m$ ) was calculated using the equation,

1176  $C_m = \tau(1/R_a + 1/R_{in})$  as previously described (Gentet et al., 2000). Two-way ANOVA in  
1177 a 2x2 factorial design was used to evaluate the statistical significance of differences  
1178 between experimental groups.

1179

1180




Fig. 1  
Li et al.




Fig. 2  
Li et al.




Figure 3  
Li et al.




Fig. 4  
Li et al.




Fig. 5  
Li et al.




Fig. 6  
Li et al.




Fig. 7

Li et al.




Fig. 8  
Li et al.

Table 1. Summary table of passive membrane properties determined in current-clamp recordings from principal neurons in slices of the BLA from different experimental groups of mice

Group	Veh_Veh	Poly I:C_Veh	Veh_LPS	Poly I:C_LPS	Poly I:C	LPS
Cell #/Mice #	21/10	24/11	15/7	20/12		
$R_{series}$ (M $\Omega$ )	17.2 $\pm$ 0.7	16.5 $\pm$ 0.6	17.1 $\pm$ 1.0	17.5 $\pm$ 0.8	$F_{(1, 76)} = 0.03$ $p = 0.871$	$F_{(1, 76)} = 0.29$ $p = 0.59$
$R_{input}$ (M $\Omega$ )	159.3 $\pm$ 12.5	155.4 $\pm$ 16.4	152.0 $\pm$ 14.5	131.0 $\pm$ 12.8	$F_{(1, 76)} = 0.71$ $p = 0.402$	$F_{(1, 76)} = 1.16$ $p = 0.285$
RMP (mV)	74.2 $\pm$ 0.9	76.1 $\pm$ 1.1	76.6 $\pm$ 1.6	72.5 $\pm$ 1.1	$F_{(1, 76)} = 0.87$ $p = 0.355$	$F_{(1, 76)} = 0.26$ $p = 0.61$
$\tau_{membrane}$ (ms)	2.7 $\pm$ 0.1	3.1 $\pm$ 0.1	3.0 $\pm$ 0.1	2.9 $\pm$ 0.1	$F_{(1, 76)} = 1.05$ $p = 0.308$	$F_{(1, 76)} = 0.41$ $p = 0.526$
$C_m$ (pF)	181.8 $\pm$ 9.1	215.3 $\pm$ 12.1	204.1 $\pm$ 11.8	196.3 $\pm$ 7.4	$F_{(1, 76)} = 1.48$ $p = 0.228$	$F_{(1, 76)} = 0.02$ $p = 0.877$